

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number
WO 2004/000347 A1

(51) International Patent Classification⁷: **A61K 38/36**, (74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsvaerd (DK).

(21) International Application Number:
PCT/DK2003/000419

(22) International Filing Date: 20 June 2003 (20.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2002 00963 21 June 2002 (21.06.2002) DK
60/394,153 3 July 2002 (03.07.2002) US

(71) Applicant (*for all designated States except US*): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): JENSEN, Michael, Bech [DK/DK]; Tokkekøbvej 22, DK-3450 Allerød (DK). HANSEN, Birthe, Lykkegaard [DK/DK]; Rådyrvej 5, DK-3500 Værløse (DK). KORNFELT, Troels [DK/DK]; Holmevej 17, DK-2830 Virum (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/000347 A1

(54) Title: STABILISED SOLID COMPOSITIONS OF FACTOR VII POLYPEPTIDES

(57) Abstract: The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature. The compositions comprises at least one stability agent selected from: a) a combination of an antioxidant and mannitol; b) a combination of a methionine and a polyol; c) a combination of a saccharide and mannitol; d) a combination of sucrose and a polyol ; and e) methionine. The antioxidant is e.g. homocysteine, cysteine, cystathione, methionine or glutathione. The saccharide is e.g. sucrose, dextrose, lactose, maltose, trehalose, cyclodextrins, maltodextrins or dextrans. The polyol is e.g. mannitol, sorbitol or xylitol.

Stabilised Solid Compositions of Factor VII polypeptides**FIELD OF INVENTION**

The present invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.

BACKGROUND OF THE INVENTION

Factor VII is a polypeptide involved in the blood clotting process. Today, Factor VIIa can be made by recombinant techniques (rFVIIa) and is widely used as a pro-haemostatic agent. Factor VII (human wild-type) has been described in U.S. Patent No. 4,784,950. rFVIIa offers today a rapid and highly effective pro-haemostatic response in haemophilic individuals experiencing bleeding. Advantageously, rFVIIa can be used for treating haemophilic individuals that cannot be treated with other coagulation factor products due to antibody formation. Also individuals suffering from Factor VII deficiency or individuals having a normal coagulation system but still experiencing excessive bleeding can be treated successfully with rFVIIa.

Several parameters need to be considered when developing a medicament comprising a polypeptide such as, e.g., Factor VIIa. By example, the medicament needs to be effective, safe and lead to good patient compliance. Moreover, the medicament may be formulated for parenteral administration using pharmaceutically acceptable excipients, which will have to meet with the approval of various world-wide medical regulatory agencies. For the purpose of parenteral administration, it is highly desirable that the formulation is approximately isotonic and that the pH of the formulation is in a physiologically suitable range upon injection/infusion, otherwise it may result in pain and discomfort for the patient. For a general review of protein formulations, see, for example, Cleland et al.: The development of stable protein formulations: A closer look at protein aggregation, deamidation and oxidation, Critical Reviews in Therapeutic Drug Carrier Systems 1993, 10(4): 307-377; and Wang et al., Parenteral formulations of proteins and peptides: Stability and stabilizers, Journal of Parenteral Science and Technology 1988 (Supplement), 42 (2S).

However, for medicaments comprising polypeptides the safety may directly be related to the physical and chemical stability of the polypeptide. Being a polypeptide, Factor VII or a Factor VII-related polypeptide is susceptible to physical degradation, including denaturation and aggregation such as the formation of soluble or insoluble aggregates in the form of dimers, oligomers and polymers, or to chemical degradation, including for example, hydrolysis, deamidation and oxidation. Consequently, the said physical and chemical instability may lead to

loss of activity of the Factor VII polypeptide, formation of toxic and immunogenic degradation products, serious risk of introducing thrombosis upon injection of the degraded Factor VII polypeptides, clogging of needles used for injections and risk of non-homogeneity, to name just a few.

5

Thus, it is essential to provide compositions comprising Factor VII polypeptides that is stabilised against physical and chemical degradation.

Today, recombinantly-made FVII polypeptide is provided as freeze-dried product that is meant to
10 be stored at temperatures between about 2 and about 8 °C. The requirement of cooled conditions causes a burden to and is inconvenient for the manufacturer or provider as well as the end user (the patient).

The actual recombinantly-made FVII product is NovoSeven® (Novo Nordisk A/S, Denmark) that
15 consists of 1.2 mg recombinant human Factor VIIa, 5.84 mg NaCl, 2.94 mg CaCl₂, 2 H₂O, 2.64 mg Glycylglycine, 0.14 mg polysorbate 80 and 60.0 mg mannitol. When reconstituted by 2.0 ml of water for injection (WFI), the pH is 5.5 and the thus prepared FVII-containing solution is sufficiently stable for 24 hours at room temperature.

20 The present investigators have found that upon storage of the lyophilised NovoSeven® product for 6 months at 25 °C about 6 to 7 % w/w of the initial content of the rFVIIa is present in the form of aggregates.

Thus, compositions comprising Factor VII polypeptides need to be stabilised so as allowing
25 storage and handling at ambient temperatures. However, the instability of polypeptides relates to several parameters and it is impossible to predict the proper manner of stabilising a Factor VIIa or a Factor VII-related polypeptide.

One approach of stabilising a protein relates to removal of water from the protein, e.g. such as
30 providing the protein in the form of a lyophilised cake, the final matter obtained in a freeze-drying process. However, the freeze-drying process itself is also harmful to proteins; during freeze-drying, the protein solution is first cooled until adequately frozen and bulk water in the protein solution will form ice at this stage. The protein is hereby prone to freeze-induced stress resulting in deformation and precipitation. In the next step, the so-called primary drying stage,
35 the ice sublimes and in the secondary drying stage, adsorbed or bound water is removed under elevated temperatures. During this water removal, the proteins may loose their proper conformation that is provided mainly through hydrogen bonding.

Therefore, to preserve protein conformation, activity and stability during freeze-drying, the polypeptide solution needs to be supplemented with sufficient amounts of proper excipients with cryoprotectant and/or lyoprotectant properties so as to protect the protein from freeze-induced stress and/or stress during removal of water, respectively.

5

Additionally, when providing a lyophilised product, an essential feature relates to the properties of the lyophilised cake. It needs to have good properties as to its form and structure, i.e. it should not collapse in that such collapsed cakes can be hard or even impossible to dissolve (reconstitute) before use. Conversely, the physical structure of the lyophilised cake may not be 10 too loosen and soft. Therefore, one or more so-called bulking agents are added to the protein solution before freeze-drying.

Other publications of interest regarding stabilisation of polypeptides are as follows:

15 U.S. 20010031721 A1 (American Home Products) concerns highly concentrated, lyophilised, and liquid Factor IX formulations.

WO 97/26909 (Genetics Institute) concerns lyophilised preparations of Factor IX suitable for storage and administration. The preparations may comprise sucrose or mannitol as a 20 cryoprotectant.

WO 95/28954 (Genetics Institute) concerns preparations of Factor IX suitable for storage and administration. The preparations may comprise sucrose as a cryoprotectant.

25 It is an objective of the present invention to provide stable compositions of Factor VII polypeptides, substantially without the presence of degradation products and without decreased activity of the Factor VII polypeptides, preferable after prolonged storage at ambient conditions, e.g. for at least 6 months. Furthermore, it is an objective that the stable compositions are suitable for parenteral administration so as not to cause any inconvenience for the patient.

30

SUMMARY OF THE INVENTION

It has been found by the present investigators that Factor VII polypeptides can be provided in a composition that is sufficient stable so as to allow for storage at room temperature for about at least 8 months. The investigators have found that the stabilisation relates to the proper 35 combining of some pharmaceutically acceptable excipients.

Accordingly, the present invention relates in a first aspect to stabilised compositions that have a moisture content of not more than about 3% and comprises a Factor VII polypeptide and at least one stability agent selected from the group consisting of a) to e):

- a) a combination of an antioxidant and mannitol;
- 5 b) a combination of methionine and a polyol;
- c) a combination of a saccharide and mannitol;
- d) a combination of sucrose and a polyol; and
- e) methionine.

10 In a further aspect, the invention relates to a method of preparing a stable Factor VII polypeptide comprising the steps of:

- i) Providing said Factor VII polypeptide in a solution comprising at least one stability agent selected from the group consisting of a) to e):
 - a) a combination of an antioxidant and mannitol;
 - 15 b) a combination of methionine and a polyol;
 - c) a combination of a saccharide and mannitol;
 - d) a combination of sucrose and a polyol; and
 - e) methionine;
- ii) Processing said solution so as to obtain a solid composition with a moisture content of not more than about 3 % w/w.

20

As mentioned, stabilised Factor VII polypeptides are requested so as to minimise the risk of adverse events and to improve safety and efficacy when administering Factor VII polypeptides for therapeutic purposes. Therefore, a still further aspect of the invention relates to the use of

25 Factor VII polypeptide for the preparation of a medicament for treating a Factor VII-responsive syndrome, said medicament comprising a composition comprising:

- a Factor VII polypeptide and a at least one stability agent selected from the group consisting of
 - a) a combination of an antioxidant and mannitol;
 - b) a combination of methionine and a polyol;
- 30 c) a combination of a saccharide and mannitol;
- d) a combination of sucrose and a polyol; and
- e) methionine,

35 said composition having a moisture content of not more than about 3%.

Finally, the invention relates to administering said Factor VII polypeptides for treating a Factor VII-responsive syndrome comprising administering to a subject in need thereof an effective amount of a composition comprising a Factor VII polypeptide and at least one stability agent selected from the group consisting of

- a) a combination of an antioxidant and mannitol;

- b) a combination of methionine and a polyol;
- c) a combination of a saccharide and mannitol;
- d) a combination of sucrose and a polyol; and
- e) methionine;

5 said composition having a moisture content of not more than about 3%.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to storage-stable compositions comprising Factor VII polypeptides. The compositions can be stored at room temperature for an extended period of time without causing substantial degradation of the Factor VII polypeptide. By room temperature is meant the ambient temperature inside a room; it normally ranges from about 5°C to about 40°C, such as from about 10°C to 30°C, or 15°C to 25°C.

By proper predetermined combination of particular pharmaceutically acceptable excipients, the 15 present investigators have provided stabilised compositions comprising Factor VII polypeptides, thus allowing the compositions to be stored at room temperature for an extended period of time such as at least about 8 months. Advantageously, the stabilised compositions need not to be stored at cooled conditions, such as between 2 and 8 °C.

20 The present invention also concerns storage-stable compositions that are stable for at least about 8 months upon storage at about 30 °C. The composition is preferably stored in the dark. Thus, the present invention makes it possible to store such compositions at room temperature without increasing the risk of adverse events to the patient administering such compositions. Advantageously, the improved storage-stability will also result in reduced cost in that no special 25 cooled conditions are required upon storage, further resulting in more convenient handling of the composition by the user.

The term "Factor VII polypeptide" is denoted to mean any Factor VII polypeptide that is effective in preventing or treating bleeding. This includes Factor VII polypeptides derived from blood or 30 plasma, or produced by recombinant means.

As used herein, "Factor VII polypeptide" encompasses, without limitation, Factor VII, as well as Factor VII-related polypeptides. The term "Factor VII" is intended to encompass, without limitation, polypeptides having the amino acid sequence 1-406 of wild-type human Factor VII (as 35 disclosed in U.S. Patent No. 4,784,950), as well as wild-type Factor VII derived from other species, such as, e.g., bovine, porcine, canine, murine, and salmon, said Factor VII derived from blood or plasma, or produced by recombinant means. It further encompasses natural allelic variations of

Factor VII that may exist and occur from one individual to another. Also, the degree and location of glycosylation or other post-translation modifications may vary depending on the chosen host cells and the nature of the host cellular environment. The term "Factor VII" is also intended to encompass Factor VII polypeptides in their uncleaved (zymogen) form, as well as those that have 5 been proteolytically processed to yield their respective bioactive forms, which may be designated Factor VIIa. Typically, Factor VII is cleaved between residues 152 and 153 to yield Factor VIIa.

As mentioned, the term "Factor VII polypeptides" is also denoted to mean "Factor VII-related polypeptides". The term "Factor VII-related polypeptides" are intended to encompass such 10 polypeptides in their uncleaved (zymogen) form, as well as those that have been proteolytically processed to yield their respective bioactive forms. As used herein, "Factor VII-related polypeptides" encompass, without limitation, polypeptides exhibiting substantially the same or improved biological activity relative to wild-type human Factor VII. These polypeptides include, without limitation, Factor VII or Factor VIIa that has been chemically modified and Factor VII 15 variants into which specific amino acid sequence alterations have been introduced that slightly modify or improve the biological activity of the polypeptide.

Moreover, Factor VII-related polypeptides, including variants of Factor VII exhibiting substantially the same or better biological activity than wild-type Factor VII, include without limitation 20 polypeptides having an amino acid sequence that differs from the sequence of wild-type Factor VII by insertion, deletion, or substitution of one or more amino acids.

Factor VII-related polypeptides, including variants, having substantially the same or improved biological activity relative to wild-type Factor VIIa encompass those that exhibit at least about 25 25%, preferably at least about 50%, more preferably at least about 75%, more preferably at least about 100%, more preferably at least about 110%, more preferably at least about 120%, and most preferably at least about 130% of the specific activity of wild-type Factor VIIa that has been produced in the same cell type, when tested in one or more of a clotting assay, proteolysis assay, or TF binding assay as described in the present specification.

30 In some embodiments the Factor VII polypeptides are Factor VII-related polypeptides, in particular variants, wherein the ratio between the activity of said Factor VII polypeptide and the activity of native human Factor VIIa (wild-type FVIIa) is at least about 1.25 when tested in the "In Vitro Hydrolysis Assay" (see Example 9, below); in other embodiments, the ratio is at least about 35 2.0; in further embodiments, the ratio is at least about 4.0. In some embodiments of the invention, the Factor VII polypeptides are Factor VII-related polypeptides, in particular variants, wherein the ratio between the activity of said Factor VII polypeptide and the activity of native human Factor VIIa (wild-type FVIIa) is at least about 1.25 when tested in the "In Vitro Proteolysis Assay" (see Example 9, below); in other embodiments, the ratio is at least about 2.0; in further

embodiments, the ratio is at least about 4.0; in further embodiments, the ratio is at least about 8.0.

Non-limiting examples of Factor VII variants having substantially the same or improved biological activity as wild-type Factor VII include S52A-FVII, S60A-FVII (Lino et al., *Arch. Biochem. Biophys.* 352: 182-192, 1998); L305V-FVII, L305V/M306D/D309S-FVII, L305I-FVII, L305T-FVII, F374P-FVII, V158T/M298Q-FVII, V158D/E296V/M298Q-FVII, K337A-FVII, M298Q-FVII, V158D/M298Q-FVII, L305V/K337A-FVII, V158D/E296V/M298Q/L305V-FVII, V158D/E296V/M298Q/K337A-FVII, V158D/E296V/M298Q/L305V/K337A-FVII, K157A-FVII, E296V-FVII, E296V/M298Q-FVII, 10 V158D/E296V-FVII, V158D/M298K-FVII, and S336G-FVII; FVIIa variants exhibiting increased proteolytic stability as disclosed in U.S. Patent No. 5,580,560; Factor VIIa that has been proteolytically cleaved between residues 290 and 291 or between residues 315 and 316 (Mollerup et al., *Biotechnol. Bioeng.* 48:501-505, 1995); oxidized forms of Factor VIIa (Kornfelt et al., *Arch. Biochem. Biophys.* 363:43-54, 1999); FVII variants as disclosed in PCT/DK02/00189; FVII 15 variants exhibiting increased proteolytic stability as disclosed in WO 02/38162 (Scripps Research Institute); FVII variants having a modified Gla-domain and exhibiting an enhanced membrane binding as disclosed in WO 99/20767 (University of Minnesota); FVII variants as disclosed in WO 01/58935 (Maxygen ApS); FVII variants having increased biological activity compared to wild-type FVIIa as disclosed in WO 01/83725, WO 02/22776, WO 02/077218, PCT/DK02/00635, Danish patent application PA 2002 01423, Danish patent application PA 2001 01627; WO 02/38162 (Scripps Research Institute); and FVIIa variants with enhanced activity as disclosed in JP 2001061479 (Chemo-Sero-Therapeutic Res Inst.).

Examples of factor VII or factor VII-related polypeptides include, without limitation, wild-type Factor VII, L305V-FVII, L305V/M306D/D309S-FVII, L305I-FVII, L305T-FVII, F374P-FVII, V158T/M298Q-FVII, V158D/E296V/M298Q-FVII, K337A-FVII, M298Q-FVII, V158D/M298Q-FVII, L305V/K337A-FVII, V158D/E296V/M298Q/L305V-FVII, V158D/E296V/M298Q/K337A-FVII, V158D/E296V/M298Q/L305V/K337A-FVII, K157A-FVII, E296V-FVII, E296V/M298Q-FVII, V158D/E296V-FVII, V158D/M298K-FVII, and S336G-FVII, L305V/K337A-FVII, L305V/V158D-FVII, 25 L305V/E296V-FVII, L305V/M298Q-FVII, L305V/V158T-FVII, L305V/K337A/V158T-FVII, L305V/K337A/M298Q-FVII, L305V/K337A/E296V-FVII, L305V/K337A/V158D-FVII, L305V/V158D/M298Q-FVII, L305V/V158D/E296V-FVII, L305V/V158T/M298Q-FVII, L305V/V158T/E296V-FVII, L305V/E296V/M298Q-FVII, L305V/V158D/E296V/M298Q-FVII, L305V/V158T/E296V/M298Q-FVII, L305V/V158T/E296V/M298Q-FVII, L305V/V158T/K337A/M298Q-FVII, L305V/V158T/E296V/K337A-FVII, 30 L305V/V158D/K337A/M298Q-FVII, L305V/V158D/E296V/K337A-FVII, L305V/V158D/E296V/M298Q-FVII, L305V/V158D/M298Q-FVII, L305V/V158D/E296V-FVII, L305V/V158T/M298Q-FVII, L305V/V158T/E296V-FVII, L305V/E296V/M298Q-FVII, L305V/V158D/E296V/M298Q-FVII, L305V/V158T/E296V/M298Q-FVII, L305V/V158T/E296V/M298Q-FVII, L305V/V158T/K337A/M298Q-FVII, L305V/V158T/E296V/K337A-FVII, 35 L305V/V158D/K337A/M298Q-FVII, L305V/V158D/E296V/K337A-FVII, L305V/V158D/E296V/M298Q/K337A-FVII, S314E/K316H-FVII, S314E/K316Q-FVII, S314E/L305V-FVII, S314E/K337A-FVII, S314E/V158D-FVII, S314E/E296V-FVII, S314E/M298Q-FVII, S314E/V158T-FVII, K316H/L305V-FVII, K316H/K337A-FVII, K316H/V158D-FVII, K316H/E296V-FVII, K316H/M298Q-FVII, K316H/V158T-FVII, K316Q/L305V-FVII, K316Q/K337A-FVII,

K316Q/V158D-FVII, K316Q/E296V-FVII, K316Q/M298Q-FVII, K316Q/V158T-FVII,
S314E/L305V/K337A-FVII, S314E/L305V/V158D-FVII, S314E/L305V/E296V-FVII, S314E/L305V/M298Q-
FVII, S314E/L305V/V158T-FVII, S314E/L305V/K337A/V158T-FVII, S314E/L305V/K337A/M298Q-FVII,
S314E/L305V/K337A/E296V-FVII, S314E/L305V/K337A/V158D-FVII, S314E/L305V/V158D/M298Q-FVII,
5 S314E/L305V/V158D/E296V-FVII, S314E/L305V/V158T/M298Q-FVII, S314E/L305V/V158T/E296V-FVII,
S314E/L305V/E296V/M298Q-FVII, S314E/L305V/V158D/E296V/M298Q-FVII,
S314E/L305V/V158T/E296V/M298Q-FVII, S314E/L305V/V158T/K337A/M298Q-FVII,
S314E/L305V/V158T/E296V/K337A-FVII, S314E/L305V/V158D/K337A/M298Q-FVII,
S314E/L305V/V158D/E296V/K337A-FVII, S314E/L305V/V158D/E296V/M298Q/K337A-FVII,
10 S314E/L305V/V158T/E296V/M298Q/K337A-FVII, K316H/L305V/K337A-FVII, K316H/L305V/V158D-
FVII, K316H/L305V/E296V-FVII, K316H/L305V/M298Q-FVII, K316H/L305V/V158T-FVII,
K316H/L305V/K337A/V158T-FVII, K316H/L305V/K337A/M298Q-FVII, K316H/L305V/K337A/E296V-
FVII, K316H/L305V/K337A/V158D-FVII, K316H/L305V/V158D/M298Q-FVII,
K316H/L305V/V158D/E296V-FVII, K316H/L305V/V158T/M298Q-FVII, K316H/L305V/V158T/E296V-
15 FVII, K316H/L305V/E296V/M298Q-FVII, K316H/L305V/V158D/E296V/M298Q-FVII,
K316H/L305V/V158T/E296V/M298Q-FVII, K316H/L305V/V158T/K337A/M298Q-FVII,
K316H/L305V/V158T/E296V/K337A-FVII, K316H/L305V/V158D/K337A/M298Q-FVII,
K316H/L305V/V158D/E296V/K337A-FVII, K316H/L305V/V158D/E296V/M298Q/K337A-FVII,
K316H/L305V/V158T/E296V/M298Q/K337A-FVII, K316Q/L305V/K337A-FVII, K316Q/L305V/V158D-
20 FVII, K316Q/L305V/E296V-FVII, K316Q/L305V/M298Q-FVII, K316Q/L305V/V158T-FVII,
K316Q/L305V/K337A/V158T-FVII, K316Q/L305V/K337A/M298Q-FVII, K316Q/L305V/K337A/E296V-
FVII, K316Q/L305V/K337A/V158D-FVII, K316Q/L305V/V158D/M298Q-FVII,
K316Q/L305V/V158D/E296V-FVII, K316Q/L305V/V158T/M298Q-FVII, K316Q/L305V/V158T/E296V-
FVII, K316Q/L305V/E296V/M298Q-FVII, K316Q/L305V/V158D/E296V/M298Q-FVII,
25 K316Q/L305V/V158T/E296V/M298Q-FVII, K316Q/L305V/V158T/K337A/M298Q-FVII,
K316Q/L305V/V158T/E296V/K337A-FVII, K316Q/L305V/V158D/K337A/M298Q-FVII,
K316Q/L305V/V158D/E296V/K337A-FVII, K316Q/L305V/V158D/E296V/M298Q/K337A-FVII,
K316Q/L305V/V158T/E296V/M298Q/K337A-FVII, F374Y/K337A-FVII, F374Y/V158D-FVII,
F374Y/E296V-FVII, F374Y/M298Q-FVII, F374Y/V158T-FVII, F374Y/S314E-FVII, F374Y/L305V-FVII,
30 F374Y/L305V/K337A-FVII, F374Y/L305V/V158D-FVII, F374Y/L305V/E296V-FVII, F374Y/L305V/M298Q-
FVII, F374Y/L305V/V158T-FVII, F374Y/L305V/S314E-FVII, F374Y/K337A/S314E-FVII,
F374Y/K337A/V158T-FVII, F374Y/K337A/M298Q-FVII, F374Y/K337A/E296V-FVII, F374Y/K337A/V158D-
FVII, F374Y/V158D/S314E-FVII, F374Y/V158D/M298Q-FVII, F374Y/V158D/E296V-FVII,
F374Y/V158T/S314E-FVII, F374Y/V158T/M298Q-FVII, F374Y/V158T/E296V-FVII, F374Y/E296V/S314E-
35 FVII, F374Y/S314E/M298Q-FVII, F374Y/E296V/M298Q-FVII, F374Y/L305V/K337A/V158D-FVII,
F374Y/L305V/K337A/E296V-FVII, F374Y/L305V/K337A/M298Q-FVII, F374Y/L305V/K337A/V158T-FVII,
F374Y/L305V/K337A/S314E-FVII, F374Y/L305V/V158D/E296V-FVII, F374Y/L305V/V158D/M298Q-FVII,
F374Y/L305V/V158D/S314E-FVII, F374Y/L305V/E296V/M298Q-FVII, F374Y/L305V/E296V/V158T-FVII,
F374Y/L305V/E296V/S314E-FVII, F374Y/L305V/M298Q/V158T-FVII, F374Y/L305V/M298Q/S314E-FVII,

F374Y/L305V/V158T/S314E-FVII, F374Y/K337A/S314E/V158T-FVII, F374Y/K337A/S314E/M298Q-FVII,
F374Y/K337A/S314E/E296V-FVII, F374Y/K337A/S314E/V158D-FVII, F374Y/K337A/V158T/M298Q-FVII,
F374Y/K337A/V158T/E296V-FVII, F374Y/K337A/M298Q/E296V-FVII, F374Y/K337A/M298Q/V158D-FVII,
F374Y/K337A/E296V/V158D-FVII, F374Y/V158D/S314E/M298Q-FVII, F374Y/V158D/S314E/E296V-FVII,
5 F374Y/V158D/M298Q/E296V-FVII, F374Y/V158T/S314E/E296V-FVII, F374Y/V158T/S314E/M298Q-FVII,
F374Y/V158T/M298Q/E296V-FVII, F374Y/E296V/S314E/M298Q-FVII,
F374Y/L305V/M298Q/K337A/S314E-FVII, F374Y/L305V/E296V/K337A/S314E-FVII,
F374Y/E296V/M298Q/K337A/S314E-FVII, F374Y/L305V/E296V/M298Q/K337A -FVII,
F374Y/L305V/E296V/M298Q/S314E-FVII, F374Y/V158D/E296V/M298Q/K337A-FVII,
10 F374Y/V158D/E296V/M298Q/S314E-FVII, F374Y/L305V/V158D/K337A/S314E-FVII,
F374Y/V158D/M298Q/K337A/S314E-FVII, F374Y/V158D/E296V/K337A/S314E-FVII,
F374Y/L305V/V158D/E296V/M298Q-FVII, F374Y/L305V/V158D/M298Q/K337A-FVII,
F374Y/L305V/V158D/E296V/K337A-FVII, F374Y/L305V/V158D/M298Q/S314E-FVII,
F374Y/L305V/V158D/E296V/S314E-FVII, F374Y/V158T/E296V/M298Q/K337A-FVII,
15 F374Y/V158T/E296V/M298Q/S314E-FVII, F374Y/L305V/V158T/K337A/S314E-FVII,
F374Y/V158T/M298Q/K337A/S314E-FVII, F374Y/V158T/E296V/K337A/S314E-FVII,
F374Y/L305V/V158T/E296V/M298Q-FVII, F374Y/L305V/V158T/M298Q/K337A-FVII,
F374Y/L305V/V158T/E296V/K337A-FVII, F374Y/L305V/V158T/M298Q/S314E-FVII,
F374Y/L305V/V158T/E296V/S314E-FVII, F374Y/E296V/M298Q/K337A/V158T/S314E-FVII,
20 F374Y/V158D/E296V/M298Q/K337A/S314E-FVII, F374Y/L305V/V158D/E296V/M298Q/S314E-FVII,
F374Y/L305V/E296V/M298Q/V158T/S314E-FVII, F374Y/L305V/E296V/M298Q/K337A/V158T-FVII,
F374Y/L305V/E296V/K337A/V158T/S314E-FVII, F374Y/L305V/M298Q/K337A/V158T/S314E-FVII,
F374Y/L305V/V158D/E296V/M298Q/K337A-FVII, F374Y/L305V/V158D/E296V/K337A/S314E-FVII,
F374Y/L305V/V158D/M298Q/K337A/S314E-FVII, F374Y/L305V/E296V/M298Q/K337A/V158T/S314E-
25 FVII, F374Y/L305V/V158D/E296V/M298Q/K337A/S314E-FVII, S52A-Factor VII, S60A-Factor VII; and
P11Q/K33E-FVII, T106N-FVII, K143N/N145T-FVII, V253N-FVII, R290N/A292T-FVII, G291N-FVII,
R315N/V317T-FVII, K143N/N145T/R315N/V317T-FVII; FVII having substitutions, additions or
deletions in the amino acid sequence from 233Thr to 240Asn, FVII having substitutions, additions
or deletions in the amino acid sequence from 304Arg to 329Cys, and FVII having substitutions,
30 deletions, or additions in the amino acid sequence Ile153-Arg223.

For purposes of the invention, biological activity of Factor VII polypeptides ("Factor VII biological activity") may be quantified by measuring the ability of a preparation to promote blood clotting using Factor VII-deficient plasma and thromboplastin, as described, e.g., in U.S. Patent No. 5,997,864. In this assay, biological activity is expressed as the reduction in clotting time relative to a control sample and is converted to "Factor VII units" by comparison with a pooled human serum standard containing 1 unit/ml Factor VII activity. Alternatively, Factor VIIa biological activity may be quantified by

- (i) Measuring the ability of Factor VIIa or a Factor VIIa -related polypeptide to produce activated Factor X (Factor Xa) in a system comprising TF embedded in a lipid membrane and Factor X. (Persson et al., J. Biol. Chem. 272:19919-19924, 1997);
- 5 (ii) Measuring Factor X hydrolysis in an aqueous system ("In Vitro Proteolysis Assay", see Example 12, below);
- (iii) Measuring the physical binding of Factor VIIa or a Factor VIIa -related polypeptide to TF using an instrument based on surface plasmon resonance (Persson, FEBS Letts. 413:359-363, 1997); and
- 10 (iv) Measuring hydrolysis of a synthetic substrate by Factor VIIa and/or a Factor VIIa -related polypeptide ("In Vitro Hydrolysis Assay", see Example 12, below); and
- (v) Measuring generation of thrombin in a TF-independent in vitro system.

The term "Factor VII biological activity" or "Factor VII activity" is intended to include the ability to generate thrombin; the term also includes the ability to generate thrombin on the surface of 15 activated platelets in the absence of tissue Factor.

Example 12 of the present specification describes in detail assays useful for assaying FVII biological activity.

20 Moreover, throughout the present specification, the terms below have the following meaning:

The term "stabilising" is intended to encompass minimising the formation of aggregates (insoluble and/or soluble) and/or chemical degradation as well as providing maintenance of pH and proper conformation of the protein during storage or production of the compositions so 25 that substantial retention of biological activity and protein stability is maintained. Moreover, stabilising is also denoted to mean lyoprotection and cryoprotection of the protein during production of the compositions at freeze-drying conditions.

The term "structural stabilisation" or "structural stability" is intended to encompass the ability to 30 form a lyophilised plug or cake with good properties and looks, e.g. such that it does not collapse and is readily dissolved before use.

The term "storage-stable" is intended to define a product that is stabilised upon storage at temperatures between 5°C - 40°C and remains within pre-selected product specifications for a 35 suitable time period - often several months.

The term "physical stability" of Factor VII polypeptides relates to the formation of insoluble and/or soluble aggregates in the form of dimeric, oligomeric and polymeric forms of Factor VII polypeptides as well as any structural deformation and denaturation of the molecule.

The term "chemical stability" is intended to relate to the formation of any chemical change in the Factor VII polypeptides upon storage in dissolved or solid state at accelerated conditions. By example are hydrolysis, deamidation and oxidation. In particular, the sulphur-containing amino acids are prone to oxidation with the formation of the corresponding sulphoxides.

The term "cryoprotectants" as used herein generally include agents, which provide stability to the protein from freezing-induced stresses. Examples of cryoprotectants include polyols such as, for example, mannitol, and include saccharides such as, for example, sucrose, as well as including surfactants such as, for example, polysorbate, poloxamer or polyethylene glycol, and the like. Cryoprotectants also contribute to the tonicity of the formulations.

The term "lyoprotectant" as used herein includes agents that provide stability to the protein during water removal upon the drying process of the lyophilisation process. For example by maintaining the proper conformation of the protein. Examples of lyoprotectants include saccharides, in particular di- or trisaccharides. Cryoprotectants may also have lyoprotectant effects.

The term "agent suitable for keeping the pH in the range of 3 to 9" encompasses those agents that maintain the solution pH in an acceptable range between 3.0 and 9.0. Typical examples of agents capable of keeping the pH within a range of 3 to 9 are the acid form or salts of citric acid, acetic acid, histidine, malic acid, phosphoric acid, tartaric acid, succinic acid, MES, HEPES, PIPES, imidazole, TRIS, lactic acid, glutaric acid and glycylglycine. It is to be understood that a combination of agents, wherein the combination of agents is suitable for maintaining the pH in the above-described range, may also be used in the present invention.

The term "lyophilised cake" as used herein is denoted to encompass the solid composition obtained upon processing a dissolved or at least a partly dissolved composition under conditions involving at least one step of cooling said dissolved/partly dissolved composition to ice followed by at least one step of vacuum drying.

The term "lyophilization" and "freeze-drying" encompasses a process during which liquid is removed from a dissolved or at least partly dissolved composition under conditions involving at least one step of cooling the dissolved or partly dissolved solution to ice followed by vacuum drying. Lyophilization, or freeze-drying, is the most common process for making solid protein pharmaceuticals. The process consists of two major steps: freezing of a protein solution, and drying of the frozen solid under vacuum. The drying step is further divided into two phases: primary and secondary drying. The primary drying removes the frozen water (sublimation of ice) and the secondary drying removes the non-frozen "bound" water (desorption of water). More

detailed analysis of each lyophilization step is provided in, e.g., Wang et al, International Journal of Pharmaceutics 203 (2000): 1-60 (see section 4, page 16 ff.).

Typically, a composition is freeze-dried by filling into vials, freezing on the shelves of the freeze-
5 dryer, after which a vacuum is established and the shelves heated to implement primary drying
(or sublimation of ice). Thereafter, secondary drying (or desorption of sorbed water) takes place
at a higher temperature until the completion of the process, i.e., where the composition contains
a sufficiently low content of moisture (water). Methods for freeze-drying are generally known in
the art, see, for example, Wang et al, International Journal of Pharmaceutics 203 (2000): 1-60.
10 It is within the ordinary skill of the practitioner to optimize the freeze-drying conditions in
regard of temperature(s), time(s) at each temperature, and also pressure that is to be used
during the process for a specific composition.

The term "moisture content" is meant to encompass water associated with the product,
15 including, without limitation, water in adsorbed form, such as unfrozen water entrapped in or
adsorbed to the frozen solute phase and/or associated with the amorphous phase or adsorbed to
the crystalline solid. The term "water content" is used interchangeably with "moisture content".
The desired residual moisture level (moisture content) is a function of the duration and the
temperature of the secondary drying step. Several methods for determining the residual
20 moisture content during lyophilization are known in the art; for example, an electronic
hygrometer or a residual gas analyser may be used. Moisture contents of freeze-dried
formulations can be determined by several methods known in the art, such as, for example, loss-
on-drying, Karl Fischer titration, thermal gravimetric analysis (TGA), gas chromatography (GC), or
near IR (see, e.g. Wang et al, International Journal of Pharmaceutics 203 (2000): 1-60). Methods
25 for determining water contents (moisture contents) are also described in both the European and
U.S. Pharmacopoeias. For example, determination of water content can be performed by Karl
Fischer coulometric titration as described in the U.S. Pharmacopoeia (USP <921, Ic>) or the
European Phamacopoeia (EP <2.5.32>).

In brief, the method is as follows:

30 *Determination of water content by coulometric titration:* The Karl Fischer reaction is used in the
coulometric determination of water based upon the quantitative reaction of water with sulphur
dioxide and iodine in an anhydrous medium. Iodine is produced electrochemically in the reaction
cell by oxidation of iodide. The iodine produced at the anode reacts immediately with the water
and the sulphur dioxide contained in the reaction cell. The amount of water in the substance is
35 directly proportional to the quantity of electricity up until the titration end-point. When all of
the water in the cell has been consumed, the end-point is reached and thus an excess of iodine
appears which is detected electrometrically thus indicating the end-point. The percentage water
content present in the substance is then calculated.

Moisture content may be defined in terms of the weight of the sample in the vial at the time of analysis (i.e. solids plus the water present- called wet weight basis) or it may be defined in terms where it is corrected for the measured water in the sample (i.e. dry weight basis). In case of freeze-dried products with low moisture contents the two measurements (wet weight basis vs.

5 dry weight basis) yield very similar results. As used herein, moisture contents are defined in terms of the solids plus the water present (i.e., wet weight basis).

The term "bulking agent" generally includes agents, which provide good lyophilised cake properties, which form a pharmaceutically elegant product, which help the protein overcome 10 various stresses, shear/freezing for example, associated with lyophilisation processes, and which help to maintain protein activity levels during the freeze-drying process and subsequent storage. Typical examples of bulking agents include mannitol, glycine, sucrose, lactose. These agents may also contribute to the tonicity of the formulations.

15 The term "tonicity modifier" is denoted to mean any agent capable of adjusting the tonicity of the composition such that upon dissolving the composition at the time of use, the composition has a tonicity within the physiological range of the blood, peritoneal fluid or other relevant body fluids. Obviously, the tonicity may also depend on whether the reconstitution solution comprises tonicity-modifying agents.

20

The term "surfactants" generally include those agents, which protect the protein from air/solution interface-induced stresses and solution/surface induced-stresses. For example surfactants may protect the protein from aggregation. Suitable surfactants may include e.g. polysorbates, polyoxyethylene alkyl ethers such as Brij 35®, or poloxamer such as Tween 20, Tween 25 80, or poloxamer 188. Preferred detergents are poloxamers, e.g. Poloxamer 188, Poloxamer 407; polyoxyethylene alkyl ethers, e.g. Brij 35®, Cremophor A25, Sympatens ALM/230; and polysorbates/Tweens, e.g. Polysorbate 20, Polysorbate 80. More preferred are Poloxamers, e.g. Poloxamer 188, and Tweens, e.g. Tween 20 and Tween 80.

30 The term "initial content" relates to the amount of Factor VII polypeptides added to a composition at the time of preparation. The concentration given herein (mg/ml) refer to either the concentration in the solution of Factor VII polypeptide before removing the moisture (e.g. before freeze-drying) or in the reconstituted composition, or is referred as % w/w, which then relates to the concentration in the solid composition, e.g. the lyophilised cake.

35

As used herein, amounts specified are understood to be \pm about 10%; thus about 50 mM includes 50 mM \pm 5mM, 4% includes 4% \pm 0.4%, etc.

As stated above, the present investigators have contributed essentially to the art by stabilising Factor VII polypeptides thereby allowing long-term storage without causing increased risk and inconvenience to the user.

- 5 The present investigators have found that a number of crucial parameters need to be adjusted in stabilising Factor VII polypeptides. One important parameter relates, at least in part, to the moisture content, e.g. water. The moisture content should be limited. As a further essential parameter, the composition should at least include one stability agent. According to the present invention, a proper stability agent includes the combination of at least two groups of
- 10 pharmaceutically acceptable excipients selected from the group consisting of antioxidants, saccharides and polyols. The saccharides and polyols have lyoprotectant and/or cryoprotectant properties that may be important, at least in part, in the event where the composition is freeze-dried. In general, improved stability may be achieved, in part, by the proper combination of at least two of these groups of excipients. However, more specifically it was found that when said
- 15 combination comprises a saccharide (sucrose) or an antioxidant (methionine), the stabilising effect may be even more significant. Moreover, it was also surprisingly found that methionine prevents oxidative degradation of the Factor VII polypeptides.

Hence in a first aspect the invention relates to a composition comprising a Factor VII polypeptide

- 20 and at least one stability agent selected from the group consisting of
 - a) a combination of an antioxidant and mannitol;
 - b) a combination of methionine and a polyol;
 - c) a combination of a saccharide and mannitol;
 - d) a combination of sucrose and a polyol; and
- 25 e) methionine,

said composition having a moisture content of not more than about 3%.

That is to say that one embodiment of the invention comprises a combination of an antioxidant and mannitol; a second embodiment comprises a combination of methionine and a polyol;

- 30 another embodiment comprises a combination of a saccharide and mannitol; in still another embodiment, the composition comprises a combination of sucrose and a polyol; and finally in another suitable embodiment, the composition comprises methionine.

As stated, the stabilising agent according to the invention includes combining at least two

- 35 groups of pharmaceutically acceptable excipients. In suitable embodiments thereof, the stabilising agent further comprises a third group of excipients. Hence, in one embodiment, the combination of an antioxidant and mannitol further comprises a saccharide. In a second embodiment thereof, the combination of methionine and a polyol further comprises a saccharide. In still interesting embodiments, the combination of a saccharide and mannitol

further comprises an antioxidant and the combination of sucrose and a polyol further comprises an antioxidant. In one embodiment, the composition of the invention comprises mannitol and sucrose; in another embodiment, the composition comprises mannitol, sucrose and methionine; in another embodiment, the composition comprises mannitol and trehalose; in another 5 embodiment, the composition comprises mannitol, trehalose and methionine

According to the invention, the Factor VII polypeptide is meant to encompass the polypeptides as described above. In suitable embodiments of the invention, the Factor VII polypeptide is selected from the group consisting of Human Factor VIIa, Recombinant Human Factor VIIa and a 10 Factor VII Sequence Variant. Preferably, the Factor VII Polypeptide is Human Factor VIIa or Recombinant Human Factor VIIa or a Factor VII-related polypeptide wherein the ratio between the activity of said Factor VII-related polypeptide and wild-type Factor VII is at least 1.25 when tested in one or more of the "In Vitro Proteolysis Assay" and the "in Vitro Hydrolysis Assay" as described in the present specification.

15 As stated, the moisture content should be limited. For the purposes of the present invention, the Factor VII polypeptides, when provided in bulk, may be provided in solid or liquid form. However, typically the Factor VII polypeptides, when provided in bulk, are in liquid form. Thus, further processing of the bulk proteins for the manufacturing of compositions requires the steps 20 of adding suitable excipients and removing the liquid from the bulk, said addition of excipients may be carried out before or after removing the liquid. One such mean for removing liquid from a protein relates to freeze-drying. Therefore, in a preferred embodiment of the present invention, the composition is in the form of a lyophilised cake. However, the present invention does not preclude other processes that are suitable for removing the liquid from the bulk 25 polypeptide so as to achieve a solid composition with moisture content of not more than about 3% w/w.

Moreover, according to the invention, the moisture content is preferably not more than about 2.5% w/w, preferably not more than about 2% w/w, most preferably not more than about 1.5% 30 w/w.

As may be understood, the invention relates, in part, to limiting the degradation of Factor VII polypeptides during preparation, e.g. during admixing of excipients and removing of liquid so as to achieve a solid composition with moisture content of the most 3% w/w, and to limiting said 35 degradation from the time of manufacturing the solid composition until the time of use, e.g. until the time when the composition is to be administered by a patient.

Therefore, as a still further parameter in stabilising compositions comprising Factor VII polypeptides, the pH should be kept in the pH range within 3 to 9 when dissolved in aqueous

solvent, such as, e.g., pure water or aqueous buffer. That is to say that the pH in the polypeptide solution at the time before removing the moisture content, e.g. before freeze-drying, should be kept within a pH of about 3 to about 9. Advantageously, this pH range is also within the desired physiological range, thereby causing no harm to the user upon administering the composition by 5 parenteral means. Preferably, the pH of the solution is from about 4.0 to about 9.0, such as 4.0 to 8.0, 4.0 to 7.5, 4.0 to 7.0, 4.5 to 7.0, 4.5 to 6.8, 4.5 to 6.5, 5.0 to 7.0, 5.0 to 6.5, 5.0 to 6.0, 5.5 to 6.5, or about 5.5 to about 6.0 such as about 5.5, 5.6, 5.7, 5.8, 5.9, or 6.0.

Hence, interesting embodiments of the invention further comprises an agent suitable for 10 keeping the pH of said composition in the range of 3 to 9 when dissolved in aqueous solution (e.g. water). Accordingly, in suitable embodiments thereof, the agent suitable for keeping the pH in the range of 3 to 9 is selected from the group consisting of acid or salts of citric acid, acetic acid, histidine, malic acid, phosphoric acid, tartaric acid, succinic acid, MES, HEPES, imidazole, TRIS, lactic acid, glutaric acid, PIPES and glycylglycine.

15 Furthermore, the suitable agent for keeping the pH in the range of 3 to 9 may also be a mixture of at least two such listed agents, wherein the mixture is able to provide a pH value in the specified range. The concentration of the suitable agents is in the range of from about 0.1 mM to 100 mM; from about 0.2 mM to 50 mM; from about 0.5 mM to 25 mM; from about 1 mM to 20 20 mM; or from about 1 mM to 10 mM.

As can be seen from Example 5 and 6, the present investigators have provided compositions with low contents of oxidised forms and aggregates upon termination of the manufacturing process, i.e. upon termination of the freeze-drying process, by combining proper amounts of mannitol (a 25 polyol), sucrose (a saccharide) and an antioxidant (methionine). Thus, the compositions according to the invention are characterised by having a low initial content of oxidised forms and aggregates before being subjected to storage.

Degradation of the Factor VII polypeptide by the oxidative pathway as well as by the 30 aggregation pathway are sensitive parameters of stability.

Typically, the compositions are stabilised upon termination of the freeze-drying such that less than 5% w/w, such as less than 4, 3 or 2% w/w of the initial content of Factor VII polypeptide is converted into its oxidised forms. The initial content of said Factor VII polypeptide being the 35 amount added to the composition upon preparation of the composition before the freeze-drying step. Moreover, less than 5% w/w, such as less than 4.0%, 3.0%, 2.5%, 2%, 1.5%, or less than 1% w/w of the initial content of Factor VII polypeptide is recovered as aggregate forms, as determined by conventional analytical methods (such as, for example, as described in the Examples of the present application).

The present investigators have found that further degradation (i.e., as calculated from the time of termination of the manufacturing process until 8 months of storage at 30 °C) of a Factor VII polypeptide is minimal upon storage under ambient conditions. As can be seen from Example 5, 5 upon storage at 30°C for 8 months the increase is such that less than 10% w/w of the initial content of Factor VII polypeptides is recovered as oxidised forms of Factor VII polypeptides in addition to the content of said oxidised forms present at the time of termination freeze-drying. Of great importance, it was found that compositions comprising an antioxidant (methionine) are more stable towards oxidative degradation of the Factor VII polypeptide.

10

Therefore, according to the present invention, suitable compositions have a limited increase in the content of oxidised forms upon storage for at least 8 months at ambient conditions.

That is to say that in still more interesting embodiments, the composition is stable such that no more than about 6% w/w of the initial content of Factor VII polypeptide is additionally degraded 15 into oxidised forms upon storage of the composition for 8 months at 30 °C after termination of the manufacturing process, e.g. freeze-drying process. In further suitable embodiments thereof, not more than about 5, 4, 3, 2, or 1.5 % w/w of the Factor VII polypeptide is additionally converted into oxidised forms, as calculated from the time of termination of the manufacturing process until 8 months of storage at 30 °C. In these embodiments of the invention the 20 compositions are stable such that not more than about 5% (4, 3, 2, or 1.5 %) w/w of the initial content of Factor VII polypeptide is converted to oxidised forms upon storage of said composition at 30 °C for 8 months. As stated above, the initial content relates to the amount of Factor VII polypeptide added to the composition upon preparation of the composition before the freeze-drying step.

25

As indicated, the degradation of Factor VII polypeptides by the aggregation pathway may also be regarded as an essential stability indicating parameter.

The present investigators have found that further degradation (i.e., as calculated from the time of termination of the manufacturing process until 8 months of storage at 30 °C) of a Factor VII 30 polypeptide is minimal upon storage under ambient conditions. As can be seen from Example 6, not more than about 5% w/w, such as not more than about 4, 3, 2.5, 2.0, 1.5, or 1.0% w/w of the content of a Factor VII polypeptide is additionally recovered as aggregates upon storage for 8 months at 30°C. Also of great importance, it was found that compositions comprising a saccharide (sucrose) are more stable towards formation of aggregates.

35

Thus, interesting embodiments of the invention relate to compositions that are stable such that not more than about 5% w/w of the initial content of Factor VII polypeptide is converted to aggregates upon storage of said composition at 30 °C for 8 months. As stated above the initial

content of said Factor VII polypeptide being the amount added to the composition upon preparation of the composition before the freeze-drying step. By proper optimisation of, at least in part, the contents of saccharides, polyols and antioxidants, the composition is stable such that not more than about 4.0%, 3.0% w/w, such as 2.5, 2.0, 1.5, or 1.0% w/w, of the initial content of Factor VII polypeptide is converted to aggregates upon storage of said composition at 30 °C for 8 months.

Thus, advantageously, the compositions of the invention have low contents of oxidised forms and aggregates upon termination of the manufacturing process, i.e. upon termination of the freeze-drying process, and thus the compositions according to the invention are characterised by having a low initial content of oxidised forms and aggregates before being subjected to storage, e.g. not more than about 5% w/w, such as 4%, 3%, or 2% w/w of the initial contents of Factor VII polypeptide is converted into an oxidised form, and less than 5% w/w, such as not more than about 4.0%, 3.0%, 2.5%, 2%, 1.5%, or not more than about 1% w/w, is converted into a dimeric or higher-order polymeric form upon termination of the manufacturing process

Moreover and advantageously, the compositions of the invention are storage-stable, e.g. less than 10% w/w, such as 6%, 5%, 4%, 3%, 2%, or 1.5% w/w of the initial contents of Factor VII polypeptide is converted into an oxidised form, and less than 5% w/w, such as 4%, 3%, 2.5%, 2%, 1.5%, or 1% w/w is converted into a dimeric or higher-order polymeric form upon storage at 30 °C for at least 8 months in the dark.

As mentioned, said improved stability relates to the proper combination of particular excipients. According to the present invention, the excipients should be selected from the group of saccharides, polyols and antioxidants in that the saccharides and polyols exhibit lyoprotectant and/or cryoprotectant properties. More specifically, in suitable embodiments according to the invention, the saccharides of interest are di- and tri-saccharides and polysaccharides such that the saccharides may be selected from the group consisting of sucrose, dextrose, lactose, maltose, trehalose, cyclodextrins, maltodextrins and dextrans. Moreover, in some embodiments, the polyol is selected from the group consisting of mannitol, sorbitol and xylitol. In still interesting embodiments, the antioxidant is selected from the group consisting of homocysteine, cysteine, cystathionine, methionine, glutathione, and peptides containing any one of homocysteine, cysteine, cystathionine, methionine and glutathione.

It is understood that the saccharide and polyol excipients, respectively, may also be a mixture of at least two such listed agents. In one series of embodiments of the invention, the saccharide excipient used is a combination of at least two di-, tri- and/or polysaccharides, such as, for example, sucrose in combination with cyclodextrin, trehalose in combination with cyclodextrin,

sucrose in combination with dextran, or sucrose in combination with lactose. In one series of embodiments of the invention, the polyol excipient used is a combination of at least two polyols, such as, for example, mannitol in combination with sorbitol, mannitol in combination with xylitol, or sorbitol in combination with xylitol. In one series of embodiments of the invention, the 5 antioxidant excipient used is a combination of at least two antioxidants, such as, for example, methionine in combination with one or more of homocysteine, cysteine, cystathionine, glutathione, and peptides containing any one of homocysteine, cysteine, cystathionine, methionine and glutathione.

10 The present investigators have recognised the proper combination of the polyols and the saccharides as well as their content so as, at least in part, to achieve favourable stability.

Hence, in some more interesting embodiments of the invention, the polyols are to be present in an amount ranging from about 5% w/w to about 90% w/w. Preferably, the amount of the polyol 15 is to be present in a range from about 18% w/w to about 88% w/w, such as from about 18% w/w to about 83% w/w, 25% to 80%, 30% to 65%, 30% to 80%, 40% to 80%, 50% to 80%, 30% to 75%, 40% to 75%, 50% to 75%, or from about 50% to about 70% w/w. The polyol are to be present in an amount ranging from about 0.5 to 75 mg/ml, such as from about 2 to 60 mg/ml, 5 mg/ml to 55 mg/ml, 8 to 45 mg/ml, 10 to 40 mg/ml, 10 to 30 mg/ml, or 20 from about 2 to 45 mg/ml, 5 mg/ml to 45 mg/ml, 5 to 35 mg/ml, 5 to 25 mg/ml, 5 to 20 mg/ml, 20 to 40 mg/ml, or such as from about 20 to 30 mg/ml,

Moreover, in interesting embodiments thereof as well as in some other interesting embodiments 25 of the invention, the saccharide is to be present in the composition in an amount ranging from about 0 to about 85% w/w. In further interesting embodiments thereof, the amount ranges from about 3% w/w to about 80% w/w, such as from about 7% w/w to about 75% w/w, 10% to 70%, 10% to 50%, 20% to 50%, 10% to 40%, or from about 10% w/w to about 35% w/w. The saccharide should be in an amount ranging from about 0.5 to 75 mg/ml, such as from about 2 to 60 mg/ml, from about 5 mg/ml to 55 mg/ml, from about 8 to 45 mg/ml, from about 10 to 40 30 mg/ml, from about 10 to 30 mg/ml, or from about 2 to 45 mg/ml, from about 5 mg/ml to 45 mg/ml, from about 5 to 35 mg/ml, from about 5 to 25 mg/ml, such as from about 5 to 20 mg/ml.

Moreover, the present investigators have recognised that the proper amounts of antioxidants should range between from about 0.05 to 10 mg/ml, such as from about 0.1 to 5 mg/ml, 0.1 35 mg/ml to 2.5 mg/ml, 0.1 to 2 mg/ml, or from about 0.1 to 1 mg/ml.

Importantly, the ratio between the polyol and the saccharide needs to be proper adjusted. In suitable embodiments of the invention, said polyol is in a weight ratio relative to said saccharide ranging from about 100:1 to 1:50. In even more suitable embodiments thereof, said weight ratio

is from about 50:1 to 1:10, more preferably from about 20:1 to 1:5. In other suitable embodiments, the weight ratio relates to ranges from about 10:1 to 1:2, and from about 6:1 to 1:2. However, as was found out by the present investigators (see Example 5), the lyophilised cake collapsed upon incorporating higher amounts of the saccharides. As such, very suitable 5 embodiments relate to those wherein said sugar alcohol is in a weight ratio relative to said saccharide ranging from about 4:1 to 1:1, such as from about 4:1 to 3:2 or from about 1:1 to 3:2.

In some embodiments of the invention, the polyol is mannitol and in still further embodiments the saccharide is sucrose. Moreover, in still further embodiments the antioxidant is methionine.

10 The compositions may further be suitable formulated by incorporating other pharmaceutically acceptable excipients so as to achieve compositions acceptable for parenteral administration, in particular to intravenous administration. Actual methods for preparing compositions for parenteral administration will be known or apparent to those skilled in the art and are described 15 in more detail in for example, Remington: The Science and Practice of Pharmacy, 19th ed., Mack Publishing Company, Easton, PA (1995). The term "excipients" includes pharmaceutical acceptable reagents to provide good lyophilised cake properties (bulking agents) as well as provide lyoprotection and cryoprotection of the protein, maintenance of pH, maintenance of acceptable tonicity as well as proper conformation of the protein during storage so that 20 substantial retention of biological activity and protein stability is maintained.

Thus, according to the invention, the compositions further comprise a tonicity modifier. The tonicity modifier may be selected from the group consisting of sodium acetate, sodium lactate, sodium chloride, potassium chloride and calcium chloride. However, other suitable tonicity 25 modifiers are not precluded. It is also noted, that compositions may comprise much higher concentrations of the tonicity-modifying agent as long as the composition is made isotonic or close to isotonic prior to use (e.g., slightly hypertonic or hypotonic), for example bulk compositions need not to be isotonic with the physiological range.

30 Further stabilisation of a composition comprising a Factor VII polypeptide can be obtained by the addition of surfactants. Thus, in still interesting embodiments of the invention, the compositions further comprising a surfactant, the surfactant being selected from the group consisting of polysorbates, e.g. Tween®, such as polysorbate 20 or 80; polyoxyethylene alkyl ethers, e.g., polyoxyl 23 lauryl ether (Brij 35®) or poloxamers, such as poloxamer 188 (e.g. Pluronic®) or 35 poloxamer 407, (e.g., Lutrol®) and other ethylene/polypropylene block polymers, polyethyleneglycols (PEG) such as PEG8000, or Typically, the surfactants are added in an amount of from 0.005 to 5 mg/ml. Preferred amounts are from 0.01 to 3 mg/ml, more preferred from 0.01 to 0.3 mg/ml for Tween 20 and/or Tween 80 and from 0.05 to 3.0 mg/ml for Poloxamer 188.

In still preferred embodiments of the invention, the composition further comprises other pharmaceutical excipients acting as bulking agent. That is to say that bulking agents other than mannitol are included in the compositions. In particular, bulking agents are included in compositions prepared by freeze-drying.

5

Initial contents of Factor VII polypeptide in the composition is preferably from about 0.6 mg/ml to about 10.0 mg/ml, such as from about 0.6 mg/ml to about 6.0 mg/ml, from about 0.6 mg/ml to about 5 mg/ml, or from about 0.6 mg/ml to about 4 mg/ml.

10 In one embodiment, the composition comprises: Factor VII polypeptide, Mannitol, Sucrose, and Tween 80, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water. In one embodiment, the composition further comprises one or more components selected from the list of: CaCl₂, NaCl, and Glycylglycine. In one embodiment, the Factor VII polypeptide is human Factor VIIa.

15

In one embodiment, the composition comprises: Factor VII polypeptide, Mannitol, Sucrose, methionine, and Tween 80, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water. In one embodiment, the composition further comprises one or more components selected from the list of: CaCl₂, NaCl, and Glycylglycine. In one embodiment, the Factor VII polypeptide is human Factor VIIa.

In another embodiment, the composition comprises Factor VII polypeptide, Mannitol, Sucrose, Histidine, and Tween 80, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water. In one embodiment, the composition further comprises one or more components selected from the list of: CaCl₂, NaCl, and Glycylglycine. In one embodiment, the Factor VII polypeptide is human Factor VIIa.

In one embodiment, the composition comprises: Factor VII polypeptide, Mannitol, Sucrose, methionine, Histidine, and Tween 80, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water. In one embodiment, the composition further comprises one or more components selected from the list of: CaCl₂, NaCl, and Glycylglycine. In one embodiment, the Factor VII polypeptide is human Factor VIIa.

35 In another embodiment, the composition comprises Factor VII polypeptide, Mannitol, Sucrose, and Poloxamer 188, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water. In one embodiment, the composition further comprises one or more components selected from the list of: CaCl₂, NaCl, and Glycylglycine. In one embodiment, the Factor VII polypeptide is human Factor VIIa.

In another embodiment, the composition comprises Factor VII polypeptide, Mannitol, Sucrose, methionine, and Poloxamer 188, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water. In one embodiment,

5 the composition further comprises one or more components selected from the list of: CaCl₂, NaCl, and Glycylglycine. In one embodiment, the Factor VII polypeptide is human Factor VIIa.

In another embodiment, the composition comprises Factor VII polypeptide, Mannitol, Sucrose, Histidine, and Poloxamer 188, has a moisture content of not more than about 3%, and has a pH
10 in the range of 5.0 to 7.0 when the composition is dissolved in water. In one embodiment, the composition further comprises one or more components selected from the list of: CaCl₂, NaCl, and Glycylglycine. In one embodiment, the Factor VII polypeptide is human Factor VIIa.

In another embodiment, the composition comprises Factor VII polypeptide, Mannitol, Sucrose,
15 Histidine, methionine, and Poloxamer 188, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water. In one embodiment, the composition further comprises one or more components selected from the list of: CaCl₂, NaCl, and Glycylglycine. In one embodiment, the Factor VII polypeptide is human Factor VIIa.

20

In further embodiments, the compositions are as shown in Table A below.

Table A

Compound	Formulation A	Formulation B	Formulation C	Formulation D
FVII polypeptide	0.6 to 10 mg/ml	0.6 to 10 mg/ml	0.6 to 10 mg/ml	0.6 to 10 mg/ml
CaCl ₂ x2H ₂ O	5 to 20 mM	5 to 20 mM	5 to 20 mM	5 to 20 mM
NaCl	0 - 50 mM	0 - 50 mM	0 - 50 mM	0 - 50 mM
Glycylglycine	0 - 15 mM	0 - 15 mM	0 - 15 mM	0 - 15 mM
L-Histidine	0 - 20 mM	0 - 20 mM	0 - 20 mM	0 - 20 mM
Mannitol	20 to 40 mg/ml	20 to 40 mg/ml	20 to 40 mg/ml	20 to 40 mg/ml
Sucrose	5 to 20 mg/ml	-	-	5 to 20 mg/ml
Methionine	0 - 1 mg/ml	0 - 1 mg/ml	0 - 1 mg/ml	0 - 1 mg/ml
Tween 80	0.05 to 0.15 mg/ml	0.05 to 0.15 mg/ml		
Poloxamer 188	-	-	0.5 - 3 mg/ml	0.5 - 3 mg/ml
pH	5.0 to 7.0	5.0 to 7.0	5.0 to 7.0	5.0 to 7.0

In further embodiments, the compositions are as shown in Table B below

25 Table B

Compound	Formulation E	Formulation F	Formulation G	Formulation H
FVIIa polypeptide	1.0 mg/ml	1.0 mg/ml	1.0 mg/ml	1.0 mg/ml
CaCl ₂ x2H ₂ O	10 mM	10 mM	10 mM	10 mM
NaCl	39 mM	39 mM	39 mM	39 mM
Glycylglycine	10 mM	10 mM	10 mM	10 mM
Mannitol	25 mg/ml	25 mg/ml	25 mg/ml	25 mg/ml
Sucrose	10 mg/ml	10 mg/ml	10 mg/ml	10 mg/ml
Methionine	0.5 mg/ml	0.5 mg/ml	0.5 mg/ml	0.5 mg/ml
Tween 80	0.1 mg/ml	-	0.1 mg/ml	-
Poloxamer 188	-	1.0 mg/ml		1.0 mg/ml
L-Histidine	-	-	10 mM	10 mM
pH	6.0	6.0	6.0	6.0

Table B (continued)

Compound	Formulation I	Formulation J	Formulation K	Formulation L
FVII polypeptide	1.0 mg/ml	1.0 mg/ml	1.0 mg/ml	1.0 mg/ml
CaCl ₂ x2H ₂ O	10 mM	10 mM	10 mM	10 mM
NaCl	39 mM	39 mM	39 mM	39 mM
Glycylglycine	10 mM	10 mM	10 mM	10 mM
Mannitol	25 mg/ml	25 mg/ml	25 mg/ml	25 mg/ml
Sucrose	10 mg/ml	10 mg/ml	10 mg/ml	10 mg/ml
Methionine	-	-	-	-
Tween 80	0.1 mg/ml	-	0.1 mg/ml	-
Poloxamer 188	-	1.0 mg/ml		1.0 mg/ml
L-Histidine	-	-	10 mM	10 mM
pH	6.0	6.0	6.0	6.0

In further embodiments E1 – L1, the compositions contains the excipients, and amounts thereof, listed in Table B above, but are formulated at pH 5.9.

In further embodiments E2 – L2, the compositions contains excipients, and amounts thereof, as listed in Table B above, but are formulated at pH 5.8.

In further embodiments E3 – L3, the compositions contains excipients, and amounts thereof, as listed in Table B above, but are formulated at pH 5.7.

10 In further embodiments E4 – L4, the compositions contains excipients, and amounts thereof, as listed in Table B above, but are formulated at pH 5.6.

In further embodiments E5 – L5, the compositions contains excipients, and amounts thereof, as listed in Table B above, but are formulated at pH 5.5.

As discussed above, the present investigators have provided a method for stabilising Factor VII polypeptides by providing the proteins in solid compositions comprising selected pharmaceutically acceptable excipients, of which it is important to include a stabilising agent. According to the invention, such a stabilising agent is composed of a combination of at least two groups of excipients selected from excipients being saccharides, polyols or antioxidants.

Moreover, the present investigators have found that saccharides (sucrose) and antioxidants (methionine) are essential for improving the stability of Factor VII polypeptides.

Therefore, a further aspect of the invention relates to a method of preparing a stable Factor VII polypeptide. The method comprises the steps of:

- i) Providing said Factor VII polypeptide in a solution comprising at least one stability agent selected from the group consisting of
 - a) a combination of an antioxidant and mannitol;
 - b) a combination of methionine and a polyol;
 - c) a combination of a saccharide and mannitol;
 - d) a combination of sucrose and a polyol; and
 - e) methionine
- ii) Processing said solution so as to obtain a solid composition with a moisture content of not more than about 3 % w/w.

20

In particular interesting embodiments thereof, the method comprises that said antioxidant is selected from the group consisting of homocysteine, cysteine, cystathionine, methionine, glutathione, and peptides containing any one of homocysteine, cysteine, cystathionine, methionine and glutathione. In a preferred embodiment, the antioxidant is methionine. In still further interesting embodiments, said saccharide is selected from the group consisting of sucrose, dextrose, lactose, maltose, trehalose, cyclodextrins, maltodextrins and dextrans. In preferable embodiments the polyol is mannitol and the saccharide is sucrose. Moreover, in still preferable embodiments thereof, the antioxidant is methionine.

30 Preferably the content of the saccharide and optionally the content of the antioxidant in said solution i) should be adjusted so as to achieve superior stabilised Factor VII polypeptides.

According to the invention, the saccharide should be in an amount ranging from about 0.5 to 75 mg/ml, such as from about 2 to 60 mg/ml, from about 5 mg/ml to 55 mg/ml, from about 8 to 45 mg/ml, from about 10 to 40 mg/ml, from about 10 to 30 mg/ml, or from about 2 to 45 mg/ml, from about 5 mg/ml to 45 mg/ml, from about 5 to 35 mg/ml, from about 5 to 25 mg/ml, such as from about 5 to 20 mg/ml.

According to the invention, the polyol should be in an amount ranging from about 0.5 to 75 mg/ml, such as from about 2 to 60 mg/ml, from about 5 mg/ml to 55 mg/ml, from about 8 to 45 mg/ml, from about 10 to 40 mg/ml, from about 10 to 30 mg/ml, or from about 2 to 45 mg/ml, from about 5 mg/ml to 45 mg/ml, from about 5 to 35 mg/ml, from about 5 to 25 mg/ml, such as 5 from about 5 to 20 mg/ml.

The antioxidant should be provided in an amount ranging from about 0.05 to 10 mg/ml, preferably from about 0.1 to 5 mg/ml, more preferably from about 0.1 mg/ml to 2.5 mg/ml, even more preferably from about 0.1 to 2 mg/ml, most preferably from about 0.1 to 1 mg/ml.

In a preferred embodiment, the method for preparing a stable Factor VII polypeptide comprises freeze-drying. The freeze-drying relates to a process, wherein the solution comprising said Factor VII polypeptide is filled into lyophilisation vials or the like. Said Factor VII polypeptide may optionally be subjected to sterile filtration before start of freeze-drying. Cooling is applied to the shelves of the freeze-drier in order to freeze the vials and the solution below critical product temperatures. Water is removed by introducing vacuum and condensation of water vapour on the ice-condenser of the freeze-drier. When the product is dry, usually less than 3% residual moisture content (e.g., measured by Karl Fischer coulometric titration as described above), the vials are closed and capped. Manufacturing is finalised and the composition is now in a form of a 10 lyophilised cake.

Such compositions, when administered to a patient by injectable means, need to be reconstituted in a suitable liquid before use. They may also be reconstituted for other purposes, e.g. for reformulation into other pharmaceutical compositions. However, the present invention 15 does not preclude that the compositions may be administered to a patient in their solid form.

The compositions are reconstituted using an acceptable, preferably sterile, diluent or carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water (e.g. Water for Injection/WFI), buffered water, saline (e.g. 0.4% saline), glycine (e.g. 0.3% glycine), histidine, 20 and the like. The reconstitution diluent may also contain one or more salts, such as a calcium salt (e.g. CaCl₂) or a combination of a sodium salt and a calcium salt (e.g. NaCl and CaCl₂).

The reconstituted compositions are intended for parenteral administration for prophylactic and/or therapeutic treatment. Preferably, the pharmaceutical compositions are administered 25 parenterally, i.e., intravenously, subcutaneously, or intramuscularly, or they are administered by way of continuous or pulsative infusion.

Therefore, a still further aspect of the invention relates to the use of the solid stabilised composition for the preparation of a medicament for treating a Factor VII-responsive syndrome.

That is to say that one aspect of the invention relates to the use of Factor VII polypeptide for the preparation of a medicament for treating a Factor VII-responsive syndrome, said medicament comprising a composition comprising;

- 5 a Factor VII polypeptide and at least one stability agent selected from the group consisting of
 - a) a combination of an antioxidant and mannitol;
 - b) a combination of methionine and a polyol;
 - c) a combination of a saccharide and mannitol;
 - d) a combination of sucrose and a polyol; and
- 10 e) methionine,

said composition having a moisture content of not more than about 3%.

Furthermore, in another aspect the invention relates to administering said stabilised Factor VII polypeptide to a patient for treating a Factor VII-responsive syndrome. Thus, the invention

- 15 relates to a method of treating a Factor VII-responsive syndrome comprising administering to a subject in need thereof an effective amount of a composition comprising a Factor VII polypeptide, and at least one stability agent selected from the group consisting of
 - a) a combination of an antioxidant and mannitol;
 - b) a combination of methionine and a polyol;
- 20 c) a combination of a saccharide and mannitol;
- d) a combination of sucrose and a polyol; and
- e) methionine;

said composition having a moisture content of not more than about 3%.

- 25 In different embodiments, said Factor VII-responsive syndrome is haemophilia A, haemophilia B, Factor XI deficiency, Factor VII deficiency, thrombocytopenia, von Willebrand's disease, presence of a clotting Factor inhibitor, surgery or trauma. Additionally, Factor VII-responsive syndrome may be associated with anticoagulant therapy.
- 30 As stated the composition is in solid form. Accordingly, in a suitable embodiment the medicament should be suitable for being dissolved, which allows for parenteral administration of the medicament. Thus, when administering the compositions to a patient, it comprises the step of dissolving the composition in a suitable liquid prior to the administering step.

35 Abbreviations used herein:

FVII	Coagulation Factor VII in its single chain form
FVIIa	Coagulation Factor VII in its cleaved, activated two-chain form
rFVII (rFVIIa)	Recombinant Factor VII (recombinant Factor VIIa)

The following examples are offered by way of illustration, not by way of limitation:

EXAMPLES

5 Example 1

Compositions comprising Factor VII polypeptides and prepared according to Example 2 are shown. Typical excipients and their typical amounts are shown.

Table 1 shows the concentration of active ingredients and excipients in the event where the composition is in liquid form, that is, in the composition before finalising the manufacturing (e.g. finalising the freeze-drying), or in the reconstituted solution.

Table 2 shows the concentration of active ingredient and excipients in the event where the composition is in solid form, i.e. in freeze-dried form.

15

Table 1. Compositions, content of excipients in solution.

Main Function:	Excipients:	Content (mg/ml) in liquid composition
Active Ingredient	rFVIIa	0.6 - 5
Tonicity modifier	Sodium Chloride	0 - 4
Tonicity modifier/stabiliser	Calcium Chloride, 2H ₂ O	1 - 7
Buffering agent	Glycylglycine	1.32 (0-1.5)
Surfactant	Polysorbate 80	0.05 - 2
Bulking Agent/Cryoprotectant/Lyoprotectant	Mannitol	10 - 40
Bulking Agent/Cryoprotectant/Lyoprotectant	Sucrose	10 - 40
Antioxidant	Methionine	0 - 1.0
	pH	5-6

Table 2. Compositions, content of excipients in freeze-dried form.

Main Function:	Excipients:	Content (% w/w) in solid composition
Active Ingredient	rFVIIa	0.6 – 19
Tonicity modifier	Sodium Chloride	0 – 15

Tonicity modifier/ stabiliser	Calcium Chloride, 2H ₂ O	1.0 to 24.0
Buffering agent	Glycylglycine	0 - 6.0
Surfactant	Polysorbate 80	0.05 - 8.0
Bulking Agent/ Cryoprotectant/ Lyoprotectant	Mannitol	13 - 76
Bulking Agent/ Cryoprotectant/ Lyoprotectant	Sucrose	13 - 76
Antioxidant	Methionine	0 - 4.2
	pH	5 - 6

Example 2.**Manufacturing of compositions**

In general, the compositions were prepared from a purified bulk solution. Excipients were added, and the solution was diluted to the desired concentration of rFVIIa. The resulting solution was sterile filtered using a sterilised membrane filter (0.2 micron pore size or equivalent) and filled into sterile glass vials. The vials were freeze-dried, stoppered and sealed with aluminium flip-off type caps.

10 Example 3.

Compositions 1-19 comprising various amounts of sodium chloride, mannitol, sucrose and methionine and with various pH values were prepared according to the process described in Example 2. The compositions comprised fixed concentrations of Factor VII (1.0 mg/ml), Calcium Chloride, 2H₂O (1.47 mg/ml), Glycylglycine (1.32 mg/ml) and Polysorbate 80 (1.0 mg/ml).

15

Table 3. Compositions 1-19.

Composition No	Composition 1-19. Content of excipients mg/ml				
	NaCl	Mannitol	Sucrose	Methionine	pH
1	0	10	10	0	6.0
2	3.5	10	10	0	5.0
3	0	40	10	0	5.0

Composition No	Composition 1-19. Content of excipients mg/ml				
	NaCl	Mannitol	Sucrose	Methionine	pH
4	3.5	40	10	0	6.0
5	0	10	40	0	5.0
6	3.5	10	40	0	6.0
7	0	40	40	0	6.0
8	3.5	40	40	0	5.0
9	0	10	10	0.5	5.0
10	3.5	10	10	0.5	6.0
11	0	40	10	0.5	6.0
12	3.5	40	10	0.5	5.0
13	0	10	40	0.5	6.0
14	3.5	10	40	0.5	5.0
15	0	40	40	0.5	5.0
16	3.5	40	40	0.5	6.0
17	1.75	25	25	0.25	5.5
18	1.75	25	25	0.25	5.5
19	1.75	25	25	0.25	5.5

Example 4**Analytical methods used in determining stability indicating parameters:**

5

A. Determination of Oxidised forms by Reverse Phase HPLC (RP-HPLC):

HPLC Column: 4.5x250 mm column packed with butylbonded silica with a particle size of 5µm and pore size 300Å. Column temperature: 70°C. Eluent A: water 99.9% v/v and trifluoracetic acid 10 0.1 % v/v. Eluent B: acetonitrile 80% v/v. trifluoracetic acid 0.09% v/v and water 19.91 % v/v. The column was eluted with a linear gradient from X% B to (X+13)% B in 30 minutes. Flow rate: 1.0 ml/min. Detection: 214 nm.

The oxidised forms are methionine sulfoxides of Factor VII Polypeptides. For example the two main derivatives of FVII are Met(O)298 FVII and Met(O)306 FVII.

The content of oxidised forms is expressed as the percentage of the initial amount of Factor VII in the composition upon preparation that is recovered as oxidised forms of Factor VII.

B. Determination of aggregates of Factor VII polypeptides by High Performance Gel Permeation
5 Chromatography (GP-HPLC).

GP-HPLC was run on a Waters Protein Pak 300 SW column, 7.5x300 mm, using 0.2 M ammoniumsulfat pH 7.0 containing 5% isopropanol as the mobile phase. Flow rate: 0.5 ml/min and detection: 215 nm.

10

The content of aggregates is expressed as the percentage of the initial amount of Factor VII in the composition upon preparation that is recovered as dimeric, oligomeric and polymeric forms of Factor VII.

15 Example 5

Content of oxidised forms of Factor VIIa after termination of the freeze-drying process and upon storage:

Compositions 1-19 of Example 3 were analysed by method A (Example 4) for content of oxidised
 20 forms upon termination of the freeze-drying and upon 2 and 8 months of storage at 30°C.

Table 4. Content of oxidised forms and increase thereof upon storage for 8 months.

% of the initial content of Factor VIIa recovered as oxidised forms.				
Composition No	0	2	8	increase 0-8 months
1	2.5	3.5	4.8	2.3
2	2.7	3	6.1	3.4
3	2.3	3.7	7	4.7
4	2.7	5.5	12	9.3
5	2.6	3.6	5.3	2.7
6	2.7	3.3	5.8	3.1
7	3	3.5	5.2	2.2
8	2.3	2.9	3.4	1.1
9	1.6	1.5	1.7	0.1
10	1.7	1.7	2.1	0.4
11	1.7	1.8	2.5	0.8

% of the initial content of Factor VIIa recovered as oxidised forms.				
Composition No	0	2	8	increase 0-8 months
12	1.6	1.6	1.9	0.3
13	1.7	1.6	1.7	0
14	1.6	1.5	1.6	0
15	1.6	1.5	1.8	0.2
16	1.7	1.6	1.8	0.1
17	1.7	1.6	n.a.	n.a.
18	1.7	1.6	1.9	0.2
19	1.7	1.6	1.8	0.1

n.a. not analysed

A statistical analysis shows that compositions comprising methionine are more stable towards oxidative degradation.

5

Example 6

Content of aggregates of Factor VIIa after termination of the freeze-drying process and upon storage:

10

Compositions 1-19 of Example 3 were analysed by method B (Example 4) for content of aggregates upon termination of the freeze-drying and upon 2 and 8 months of storage at 30°C.

Table 5. Content of aggregates and their increase upon storage for 8 months.

% of the initial content of Factor VIIa recovered as aggregates.				
Composition No	0	2	8	increase 0-8 months
1	0.7	0.8	0.9	0.2
2	1	2	2.9	1.9
3	1.5	2.5	3.5	2
4	1.1	2.1	3.1	2
5	0.8	1	1.1	0.3
6	0.8	1.2	1.1	0.3
7	0.9	1	0.9	0
8	0.9	1	1.2	0.3
9	0.9	1	1.1	0.2

10	0.8	1.7	2.5	1.7
11	1	1.2	1.5	0.5
12	1.3	2	2.8	1.5
13	0.7	0.8	0.9	0.2
14	1	1.7	1.4	0.4
15	1.1	1.4	1.5	0.4
16	0.8	0.9	1	0.2
17	0.9	1.1	n.a.	n.a.
18	0.8	1	1.5	0.7
19	1	1	1.1	0.1

n.a. not analysed

A statistical analysis shows that the presence of sucrose in the compositions is important in order to decrease formation of aggregates.

5

Example 7

Content of dimeric and oligomeric forms of Factor VIIa after termination of the freeze-drying process:

10 Composition A comprising polyol and saccharide as listed in the table below was prepared according to the process described in Example 2. The composition further comprised Factor VIIa (1.0 mg/ml), calcium chloride 2 H₂O (1.47 mg/ml), glycylglycine (1.32 mg/ml) and polysorbate 80 (0.7 mg/ml). pH was 5.0.

15 Composition A was analysed by method B (Example 4) for content of aggregates upon termination of the freeze-drying and upon 1 and 2 months of storage at 30°C. The table lists the % of the initial content of Factor VIIa recovered as aggregates:

Table 6.

% of the initial content of Factor VIIa recovered as aggregates.				
Composition	Additives	Months		
		0	1	2
A	Mannitol 25 mg/ml Trehalose 15 mg/ml	1.1	2.0	1.7

20

Example 8

Structural stability of the freeze-dried cake is shown for various compositions, 1-19, see Example 3. The ratio of mannitol to sucrose is reported of each composition.

Table 7. Stability of the freeze-dried cake according to the ratio between mannitol and sucrose

	Compositions			
	5, 6, 13, 14	1, 2, 7, 8, 9, 10, 15, 16	17, 18 and 19	3, 4, 11, 12
Weight Ratio of Man : Suc	1:4	1:1	1:1	4:1
Freeze-dried cake	C	OK	OK	OK

5 C : collapsed cake, Man: Mannitol, Suc: Sucrose, OK: slightly collapsed or not collapsed

Example 9

The following formulations were prepared as described in example 2 using filling volumes of 1 and 5 ml:

10

Formulation	A	B	C
rFVIIa (mg/ml)	0.6	1.0	1.0
CaCl ₂ (mM)	10	10	10
Glycylglycine	10	10	10
L-Histidine (mM)	-	10	10
NaCl (mM)	50	39	39
Tween 80 (mg/ml)	0.038	0.07	0.07
Methionine (mg/ml)	-	0.5	2.0
Mannitol (mg/ml)	30	25	25
Sucrose (mg/ml)	-	10	10
Ph	5.5	5.5	5.5

The stability of the formulations was investigated at 25°C, 30°C, and 40°C and the following results were obtained. The vials were reconstituted in water before analysis.

15 Dimer and oligomer forms

The contents of dimer and oligomer forms were measured by GP-HPLC as described in example 4. All results are stated in %.

5 ml filling volume:

Formulation	0 months	½ month	1 month	3 months			6 months
				40°C	40°C	40°C	
A	3.3	5.5	6.4	8.0	6.0	6.3	6.3
B	2.3	2.7	2.8	3.0	2.7	3.2	3.0
C	4.0	4.2	4.6	4.7	4.3	4.4	4.4

20

1 ml filling volume:

Formulation	0 months	3 months		
		40°C	30°C	25°C
A	2.7	11.0	7.0	6.5
B	2.2	7.4	3.4	2.9
C	3.3	6.9	3.8	3.7

Furthermore, the contents of aggregate forms for formulation A (= Ref) and formulation B (= New), filling volume 5 ml, can be seen from Figure 2a.

10

Oxidised forms

The contents of oxidised forms were measured by RP-HPLC as described in example 4.

5 ml filling volume:

Formulation	0 months	½ month	1 month	3 months			6 months
				40°C	30°C	25°C	25°C
A	2.1	2.8	3.4	4.0	3.4	3.1	3.5
B	1.3	1.3	1.6	1.3	1.6	1.6	1.4
C	1.2	1.4	1.6	1.8	1.6	1.6	1.3

15

1 ml filling volume:

Formulation	0 months	3 months		
		40°C	30°C	25°C
A	2.5	4.6	4.0	5.3
B	1.3	2.0	1.1	1.8
C	1.3	1.8	1.7	1.5

Furthermore, the contents of oxidized forms for formulation A (= Ref) and formulation B (= New),

25 filling volume 5 ml, can be seen from Figure 2b.

Activity

The activity was measured by one stage clotting assay as described in example 12 for formulations, which had been stored at 30°C for 3 months. The specific activity was calculated based on the content

30 of rFVIIa in the formulations and the following results were obtained:

Formulation	Specific activity (IU/mg)
A	50523
B	58373
C	60318

Interpretation of results:

The results show, that formulations B and C, which contain mannitol, sucrose, and methionine are
35 more stable – i.e. shows a slower increase in contents of dimer and oligomer forms and oxidised forms. In accordance, the activities of these formulations are higher as measured after 3 months' storage at 30°C.

PAGE INTENTIONALLY LEFT BLANK

Example 10

The following formulations were prepared as described in example 2 using a filling volume of 5 ml.

Formulation	A	B	C	D	E
rFVIIa (mg/ml)	1.0	1.0	1.0	1.0	1.0
CaCl ₂ (mM)	10	10	10	10	10
Glycylglycine (mM)	10	10	10	10	10
L-Histidine (mM)	10	10	10	10	10
NaCl (mM)	39	39	39	39	39
Methionine (mg/ml)	0.5	0.5	0.5	0.5	0.5
Tween 20 (mg/ml)	0.1				
Tween 80 (mg/ml)		0.1			
Poloxamer 188 (mg/ml)			1.0		
Brij 35 (mg/ml)				0.1	
Mannitol (mg/ml)	25	25	25	25	25
Sucrose (mg/ml)	10	10	10	10	10
pH	5.5	5.5	5.5	5.5	5.5

5 The vials were reconstituted in water and subjected to shaking for 19 hours in order to test the physical stability of the formulations. The effect of shaking was investigated by visual inspection and measurement of the UV absorbance at 400 nm (= Abs in the table below). The results below clearly show the increased physical stability obtained by addition of a detergent.

Formulation	Before shaking		After shaking	
	Visual appearance	Abs	Visual appearance	Abs
A	Clear liquid	0.01	Clear liquid with few particles	0.01
B	Clear liquid	0.00	Slightly turbid	0.36
C	Clear liquid	0.00	Clear liquid with few particles	0.00
D	Clear liquid	0.00	Clear liquid with few particles	0.00
E	Clear liquid	0.01	Turbid	2.18

Example 11

Six formulation were prepared as described in example 2. The composition of the formulations was:

rFVIIa	1.0 mg/ml
CaCl ₂	10 mM
Glycylglycine	10 mM
L-Histidin	10 mM
NaCl	39 mM
Tween 80	0.07 mg/ml
Mannitol	25 mg/ml
Sucrose	10 mg/ml

5

Each of the six formulations were adjusted to a different pH:

Formulation A: pH 5.0

Formulation B: pH 5.5

Formulation C: pH 6.0

10 Formulation D: pH 6.5

Formulation E: pH 7.0

Formulation F: pH 7.5

The stability of the six formulations was investigated for vials stored at 25°C and 40°C. The results

15 shown in the Tables below (and Figure 1a and 1b) were obtained.

Formulation	Dimer and oligomer forms (aggregates) (%)		
	0 MONTHS	40°C /3 MONTHS	25°C /3 MONTHS
A	2.2	3.8	2.5
B	1.7	3.2	1.9
C	1.5	2.7	1.7
D	1.1	1.9	1.3
E	0.8	1.6	1.0
F	0.8	1.6	1.0

Formulation	Oxidised forms (%)		
	0 MONTHS	40°C /3 MONTHS	25°C /3 MONTHS
A	2.7	3.3	3.4
B	N/A	4.0	3.6
C	2.6	5.0	3.7
D	2.5	4.9	3.6
E	2.6	10.0	4.6
F	2.6	8.7	4.7

The contents of dimers and oligomer forms and oxidised forms were determined as described in example 4.

Example 12**Assays for testing biological activity of Factor VII polypeptides:**Test for Factor VIIa activity:

5 A suitable assay for testing for Factor VIIa activity and thereby selecting suitable Factor VIIa variants can be performed as a simple preliminary *in vitro* test: (the "*In Vitro Hydrolysis Assay*").

In Vitro Hydrolysis Assay

Native (wild-type) Factor VIIa and Factor VIIa variant (both hereafter referred to as "Factor VIIa")
10 may be assayed for specific activities. They may also be assayed in parallel to directly compare their specific activities. The assay is carried out in a microtiter plate (MaxiSorp, Nunc, Denmark). The chromogenic substrate D-Ile-Pro-Arg-p-nitroanilide (S-2288, Chromogenix, Sweden), final concentration 1 mM, is added to Factor VIIa (final concentration 100 nM) in 50 mM Hepes, pH 7.4, containing 0.1 M NaCl, 5 mM CaCl₂ and 1 mg/ml bovine serum albumin. The absorbance at
15 405 nm is measured continuously in a SpectraMax™ 340 plate reader (Molecular Devices, USA). The absorbance developed during a 20-minute incubation, after subtraction of the absorbance in a blank well containing no enzyme, is used to calculate the ratio between the activities of variant and wild-type Factor VIIa:

$$\text{Ratio} = (A_{405 \text{ nm}} \text{ Factor VIIa variant}) / (A_{405 \text{ nm}} \text{ Factor VIIa wild-type}).$$

20

Based thereon, Factor VIIa variants with an activity comparable to or higher than native Factor VIIa may be identified, such as, for example, variants where the ratio between the activity of the variant and the activity of native Factor VII (wild-type FVII) is around, versus above 1.0.

25 The activity of Factor VIIa or Factor VIIa variants may also be measured using a physiological substrate such as Factor X, suitably at a concentration of 100-1000 nM, where the Factor Xa generated is measured after the addition of a suitable chromogenic substrate (eg. S-2765) ("the *In Vitro Proteolysis Assay*"). In addition, the activity assay may be run at physiological temperature.

30

In Vitro Proteolysis Assay

Native (wild-type) Factor VIIa and Factor VIIa variant (both hereafter referred to as "Factor VIIa") are assayed in parallel to directly compare their specific activities. The assay is carried out in a microtiter plate (MaxiSorp, Nunc, Denmark). Factor VIIa (10 nM) and Factor X (0.8 microM) in 100
35 microL 50 mM Hepes, pH 7.4, containing 0.1 M NaCl, 5 mM CaCl₂ and 1 mg/ml bovine serum albumin, are incubated for 15 min. Factor X cleavage is then stopped by the addition of 50 microL 50 mM Hepes, pH 7.4, containing 0.1 M NaCl, 20 mM EDTA and 1 mg/ml bovine serum albumin. The amount of Factor Xa generated is measured by addition of the chromogenic substrate Z-D-Arg-Gly-Arg-p-nitroanilide (S-2765, Chromogenix, Sweden), final concentration 0.5 mM. The absorbance at

405 nm is measured continuously in a SpectraMax™ 340 plate reader (Molecular Devices, USA). The absorbance developed during 10 minutes, after subtraction of the absorbance in a blank well containing no FVIIa, is used to calculate the ratio between the proteolytic activities of variant and wild-type Factor VIIa:

5

$$\text{Ratio} = (\text{A405 nm Factor VIIa variant}) / (\text{A405 nm Factor VIIa wild-type}).$$

Based thereon, Factor VIIa variants with an activity comparable to or higher than native Factor VIIa may be identified, such as, for example, variants where the ratio between the activity of the variant
10 and the activity of native Factor VII (wild-type FVII) is around, versus above 1.0.

Thrombin generation assay:

The ability of Factor VII or Factor VII-related polypeptides or Factor VIII or Factor VIII-related polypeptides (e.g., variants) to generate thrombin can be measured in an assay comprising all
15 relevant coagulation Factors and inhibitors at physiological concentrations and activated platelets (as described on p. 543 in Monroe et al. (1997) Brit. J. Haematol. 99, 542-547 which is hereby incorporated as reference).

Clot assay:

20 The activity of the Factor VII polypeptides may also be measured using a one-stage clot assay (assay 4) essentially as described in WO 92/15686 or US 5,997,864. Briefly, the sample to be tested is diluted in 50 mM Tris (pH 7.5), 0.1% BSA and 100 µL is incubated with 100 µL of Factor VII deficient plasma and 200 µL of thromboplastin C containing 10 mM Ca²⁺. Clotting times are measured and compared to a standard curve using a reference standard or a pool of citrated
25 normal human plasma in serial dilution.

CLAIMS

1. A composition comprising a Factor VII polypeptide, and at least one stability agent selected from the group consisting of
 - a) a combination of an antioxidant and mannitol;
 - 5 b) a combination of methionine and a polyol;
 - c) a combination of a saccharide and mannitol;
 - d) a combination of sucrose and a polyol; and
 - e) methionine,said composition having a moisture content of not more than about 3%.
- 10 2. The composition according to claim 1, wherein the combination of an antioxidant and mannitol further comprises a saccharide.
3. The composition according to claim 1, wherein the combination of methionine and a polyol
15 further comprises a saccharide.
4. The composition according to claim 1, wherein the combination of a saccharide and mannitol further comprises an antioxidant.
- 20 5. The composition according to claim 1, wherein the combination of sucrose and a polyol further comprises an antioxidant.
6. The composition according to any one of the preceding claims, wherein the antioxidant is selected from the group consisting of homocysteine, cysteine, cystathionine, methionine,
25 glutathione, and peptides containing any one of homocysteine, cysteine, cystathionine, methionine and glutathione.
7. The composition according to any one of the preceding claims, wherein the saccharide is selected from the group consisting of sucrose, dextrose, lactose, maltose, trehalose,
30 cyclodextrins, maltodextrins and dextrans.
8. The composition according to any one of the preceding claims, wherein the polyol is selected from the group consisting of mannitol, sorbitol and xylitol.
- 35 9. The composition according to any one of the preceding claims, wherein the composition is stable such that not more than about 5% w/w of the initial content of Factor VII polypeptide is converted to aggregates upon storage of said composition at 30 °C for 8 months, preferably not

more than about 4.0% w/w, 3.0% w/w, 2.5% w/w, 2.0% w/w, 1.5% w/w, or not more than about 1.0% w/w,

10. The composition according to any one of the preceding claims, wherein the composition is
5 stable such that not more than about 6% w/w of the initial content of Factor VII polypeptide is converted to oxidised forms upon storage of said composition at 30 °C for 8 months, preferably not more than about 5% w/w, 4.0% w/w, 3.0% w/w, 2.5% w/w, 2.0% w/w, or not more than about 1.5% w/w.

10 11. The composition according to any one of the preceding claims, wherein said polyol is in an amount ranging from about 5% w/w to 90% w/w, preferably from about 18% w/w to 88% w/w, 18% to 83%, 25% to 80%, 40% to 80%, 50% to 80%, or from about 50% w/w to 70% w/w.

12. The composition according to any one of the preceding claims, wherein said saccharide is in
15 an amount ranging from about 0 to 85% w/w, preferably from about 3% w/w to 80% w/w, 7% to 75%, 10% to 70%, 10% to 50%, 10% to 40%, or from about 10% w/w to 35% w/w.

13. The composition according to any one of the preceding claims, wherein said polyol is in a weight ratio relative to said saccharide ranging from about 100:1 to 1:50, preferably from about
20 50:1 to 1:10; 20:1 to 1:5; 10:1 to 1:2; 6:1 to 1:2; 4:1 to 1:1; or from about 4:1 to 3:2.

14. The composition according to any one of the preceding claims, further comprising an agent suitable for keeping the pH of said composition in the range of 3 to 9 when dissolved in aqueous solvent, preferably the pH is in the range of 4 to 7, more preferred in the range of 4.5 to 6.5,
25 even more preferred in the range of 5 to 6.

15. The composition according to claim 14, wherein said agent is selected from the group consisting of citrate, acetate, histidine, malate, phosphate, tartaric acid, succinic acid, MES, HEPES, PIPES, imidazol, TRIS, lactate, glutamate and glycylglycine.

30

16. The composition according to any one of the preceding claims, further comprising a tonicity modifier.

17. The composition according to claim 16, wherein the tonicity modifier is selected from the
35 group consisting of sodium acetate, sodium lactate, sodium chloride, potassium chloride and calcium chloride.

18. The composition according to any one of the preceding claims, further comprising a surfactant.

19. The composition according to claim 18, wherein the surfactant is selected from the group consisting of polysorbates, such as polysorbate 20 or 80; polyoxyethylene alkyl ethers such as Brij 35® or poloxamers, such as Poloxamer 188 or 407; and other ethylene/polypropylene block polymers or polyethyleneglycol (PEG) such as PEG8000.
20. The composition according to any one of the preceding claims, further comprising other pharmaceutical excipients acting as a bulking agent.
- 10 21. The composition according to any one of the preceding claims, wherein the saccharide is sucrose.
22. The composition according to any one of the preceding claims, wherein the polyol is mannitol.
- 15 23. The composition according to any one of the preceding claims, wherein the Factor VII Polypeptide is selected from the group consisting of Human Factor VIIa, Recombinant Human Factor VIIa and a Factor VII Sequence Variant.
- 20 24. The composition according to claim 23, wherein the Factor VII Polypeptide is Human Factor VIIa or Recombinant Human Factor VIIa.
- 25 25. The composition according to any one of claims 1-23, wherein the Factor VII Polypeptide is a Factor VII-related polypeptide wherein the ratio between the activity of said Factor VII-related polypeptide and wild-type Factor VII is at least 1.25 when tested in one or more of the "In Vitro Proteolysis Assay" and the "in Vitro Hydrolysis Assay" as described in the present specification.
- 30 26. The composition according to any one of claims 23 to 25, wherein Factor VII polypeptide is present in a concentration of from about 0.6 mg/ml to about 10.0 mg/ml, such as from about 0.6 mg/ml to about 6 mg/ml, from about 0.6 mg/ml to about 5 mg/ml, or from about 0.6 mg/ml to about 4 mg/ml.
- 35 27. The composition according to any one of the preceding claims, wherein said moisture content is not more than about 2.5% w/w, preferably not more than about 2% w/w, most preferably not more than about 1.5% w/w
28. The composition according to any one of the preceding claims, wherein the composition is a lyophilised cake.

29. The composition according to any one of the preceding claims, wherein the composition comprises: Factor VII polypeptide, Mannitol, Sucrose, and a surfactant selected from a polysorbate or a poloxamer, such as Tween 80® or Poloxamer 188®.

5 30. The composition according to claim 29, which further contains methionine.

31. The composition according to any one of claims 29 or 30, which further contains L-histidine.

32. The composition according to any one of claims 29 to 31, which further contains one or more
10 components selected from the list of: CaCl₂, NaCl, and Glycylglycine.

33. The composition according to any one of the preceding claims, wherein the composition is selected from the list of formulations A to D:

Compound	Formulation A	Formulation B	Formulation C	Formulation D
FVII polypeptide	0.6 to 10 mg/ml	0.6 to 10 mg/ml	0.6 to 10 mg/ml	0.6 to 10 mg/ml
CaCl ₂ x2H ₂ O	5 to 20 mM	5 to 20 mM	5 to 20 mM	5 to 20 mM
NaCl	0 - 50 mM	0 - 50 mM	0 - 50 mM	0 - 50 mM
Glycylglycine	0 - 15 mM	0 - 15 mM	0 - 15 mM	0 - 15 mM
L-Histidine	0 - 20 mM	0 - 20 mM	0 - 20 mM	0 - 20 mM
Mannitol	20 to 40 mg/ml	20 to 40 mg/ml	20 to 40 mg/ml	20 to 40 mg/ml
Sucrose	5 to 20 mg/ml	-	-	5 to 20 mg/ml
Methionine	0 - 1 mg/ml	0 - 1 mg/ml	0 - 1 mg/ml	0 - 1 mg/ml
Tween 80	0.05 to 0.15 mg/ml	0.05 to 0.15 mg/ml		
Poloxamer 188	-	-	0.5 - 3 mg/ml	0.5 - 3 mg/ml
Ph	5.0 to 7.0	5.0 to 7.0	5.0 to 7.0	5.0 to 7.0

15 34. The composition according to any one of the preceding claims, wherein the composition is selected from the list of formulations Ex to Lx:

Compound	Formulation Ex	Formulation Fx	Formulation Gx	Formulation Hx
FVIIa polypeptide	1.0 mg/ml	1.0 mg/ml	1.0 mg/ml	1.0 mg/ml
CaCl ₂ x2H ₂ O	10 mM	10 mM	10 mM	10 mM
NaCl	39 mM	39 mM	39 mM	39 mM
Glycylglycine	10 mM	10 mM	10 mM	10 mM
Mannitol	25 mg/ml	25 mg/ml	25 mg/ml	25 mg/ml
Sucrose	10 mg/ml	10 mg/ml	10 mg/ml	10 mg/ml
Methionine	0.5 mg/ml	0.5 mg/ml	0.5 mg/ml	0.5 mg/ml
Tween 80	0.1 mg/ml	-	0.1 mg/ml	-

Poloxamer 188	-	1.0 mg/ml		1.0 mg/ml
L-Histidine	-	-	10 mM	10 mM
pH	5.5 to 6.0	5.5 to 6.0	5.5 to 6.0	5.5 to 6.0

Compound	Formulation Ix	Formulation Jx	Formulation Kx	Formulation Lx
FVII polypeptide	1.0 mg/ml	1.0 mg/ml	1.0 mg/ml	1.0 mg/ml
CaCl ₂ x2H ₂ O	10 mM	10 mM	10 mM	10 mM
NaCl	39 mM	39 mM	39 mM	39 mM
Glycylglycine	10 mM	10 mM	10 mM	10 mM
Mannitol	25 mg/ml	25 mg/ml	25 mg/ml	25 mg/ml
Sucrose	10 mg/ml	10 mg/ml	10 mg/ml	10 mg/ml
Methionine	-	-	-	-
Tween 80	0.1 mg/ml	-	0.1 mg/ml	-
Poloxamer 188	-	1.0 mg/ml		1.0 mg/ml
L-Histidine	-	-	10 mM	10 mM
pH	5.5 to 6.0	5.5 to 6.0	5.5 to 6.0	5.5 to 6.0

35. The compositions according to any one of claims 29 to 34, wherein the Factor VII polypeptide
5 is human Factor VIIa.

36. A method of preparing a stable Factor VII polypeptide comprising the steps of:

- i) providing said Factor VII polypeptide in a solution comprising at least one stability agent selected from the group consisting of
- 10 a) a combination of an antioxidant and mannitol;
- b) a combination of methionine and a polyol;
- c) a combination of a saccharide and mannitol;
- d) a combination of sucrose and a polyol; and
- e) methionine
- 15 ii) processing said solution so as to obtain a solid composition with a moisture content not more than about 3 % w/w.

37. The method according to claim 36, wherein the antioxidant is selected from the group consisting of homocysteine, cysteine, cystathionine, methionine, glutathione, and peptides

- 20 containing any one of homocysteine, cysteine, cystathionine, methionine and glutathione.

38. The method according to claim 36 or claim 37, wherein the saccharide is selected from the group consisting of sucrose, dextrose, lactose, maltose, trehalose, cyclodextrins, maltodextrins and dextrans.

5 39. The method according to any one of claims 36 to 38, wherein the polyol is selected from the group consisting of mannitol, sorbitol and xylitol.

40. The method according to any one of claims 36 to 39, wherein said polyol is present in an amount ranging from about 0.5 to about 75 mg/ml, preferably from about 2 to 45 mg/ml, such 10 as from about 5 mg/ml to 45 mg/ml, from about 5 to 35 mg/ml, from about 5 to 25 mg/ml, 5 to 20 mg/ml, 20 to 40 mg/ml, or from about 20 to about 30 mg/ml,

41. The method according to any one of claims 36 to 40, wherein said saccharide is present in an amount ranging from about 0.5 to 75 mg/ml, preferably from about 2 to 45 mg/ml, such as from 15 about 5 mg/ml to 45 mg/ml, from about 5 to 35 mg/ml, from about 5 to 25 mg/ml, or from about 5 to 20 mg/ml.

42. The method according to any one of claims 36 to 41, wherein said antioxidant is in an amount ranging from about 0.05 to 10 mg/ml, preferably from about 0.1 to 5 mg/ml, more 20 preferably from about 0.1 mg/ml to 2.5 mg/ml, even more preferably from about 0.1 to 2 mg/ml, most preferably from about 0.1 to 1 mg/ml.

43. The method according to any one of claims 36 to 42, wherein the saccharide is sucrose.

25 44. The method according to any one of claims 36 to 43, wherein the antioxidant is methionine.

45. The method according to any one of claims 36 to 43, wherein the polyol is mannitol.

46. The method according to any one of claims 36 to 45, wherein said processing comprises 30 freeze-drying.

47. A method for treating a Factor VII-responsive syndrome comprising administering to a subject in need thereof an effective amount of a composition comprising a Factor VII polypeptide, and at least one stability agent selected from the group consisting of
35 a) a combination of an antioxidant and mannitol;
b) a combination of methionine and a polyol;
c) a combination of a saccharide and mannitol;
d) a combination of sucrose and a polyol; and
e) methionine;

said composition having a moisture content not more than about 3%.

48. The method according to claim 47, wherein said syndrome is selected from the group consisting of haemophilia A, haemophilia B, Factor XI deficiency, Factor VII deficiency, 5 thrombocytopenia, von Willebrand's disease, presence of a clotting factor inhibitor, surgery, trauma, dilutional coagulopathy, and anticoagulant therapy.

49. The method according to any one of claims 47 or 48, comprising the step of dissolving the composition in a suitable liquid prior to the administering steps.

10

50. The method according to any one of claims 47 to 49, wherein the composition is as defined by any one of claims 1 to 33.

51. Use of Factor VII polypeptide for the preparation of a medicament for treating a Factor VII-15 responsive syndrome, said medicament comprising a composition comprising; a Factor VII polypeptide and a at least one stability agent selected from the group consisting of a) a combination of an antioxidant and mannitol; b) a combination of methionine and a polyol; c) a combination of a saccharide and mannitol; 20 d) a combination of sucrose and a polyol and e) methionine, said composition having a moisture content not more than about 3%.

52. The use according to claim 51, wherein said syndrome is selected from the group consisting 25 of haemophilia A, haemophilia B, Factor XI deficiency, Factor VII deficiency, thrombocytopenia, von Willebrand's disease, presence of a clotting factor inhibitor, surgery, trauma, and anticoagulant therapy.

53. The use according to any one of claims 51 or 52, wherein the medicament is suitable for 30 being dissolved.

54. The use according to any one of claims 51 to 53, wherein the composition is as defined by any one of claims 1 to 35.

35 Novo Nordisk A/S

1/2




Fig 1a

5




Fig 1b

2/2




Fig 2a




Fig 2b

INTERNATIONAL SEARCH REPORT

Inter

Application No
PCT/DK 03/00419A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K38/36 A61P7/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 48635 A (BESMAN MARC ;BJORNSON ERIK (US); PIKAL MICHAEL (US); CARPENTER JOH) 24 August 2000 (2000-08-24) page 9 -page 12 page 29 -page 30; table 12 ---	1-54
X	WO 93 00807 A (CRYOLIFE INC) 21 January 1993 (1993-01-21) page 1, line 4 - line 7 page 3, line 11 - line 23 page 6, line 25 - line 28 page 7, line 10 - line 20 page 8, line 27 page 8, line 31 ---	1,7-29, 31,32, 35,36, 38-43, 45-54
Y	---	1-54

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 October 2003

Date of mailing of the international search report

20.10.03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

CAROLINA PALMCRANTZ/EL

INTERNATIONAL SEARCH REPORT

International Application No
PCT/DK 03/00419

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94 26286 A (KABI PHARMACIA AB ;OESTERBERG THOMAS (SE); FATOUROS ANGELICA (SE)) 24 November 1994 (1994-11-24) page 6, line 8 - line 32 page 7, line 4 - line 19 abstract -----	1-54

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 03/00419

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: **47-50**
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 47-50

Claims 47-50 relate to methods for treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l	Application No
PCT/DK 03/00419	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0048635	A 24-08-2000	AU 2884300 A		04-09-2000
		BR 0008405 A		30-04-2002
		CA 2362927 A1		24-08-2000
		CN 1399560 T		26-02-2003
		CZ 20012996 A3		13-03-2002
		EP 1154796 A1		21-11-2001
		JP 2003520764 T		08-07-2003
		WO 0048635 A1		24-08-2000
		US 6586573 B1		01-07-2003
-----	-----	-----	-----	-----
WO 9300807	A 21-01-1993	AU 2309692 A		11-02-1993
		WO 9300807 A1		21-01-1993
-----	-----	-----	-----	-----
WO 9426286	A 24-11-1994	AT 218354 T		15-06-2002
		AU 681883 B2		11-09-1997
		AU 6659794 A		12-12-1994
		CA 2161350 A1		24-11-1994
		CN 1122573 A ,B		15-05-1996
		CZ 9502869 A3		15-05-1996
		DE 69430745 D1		11-07-2002
		DE 69430745 T2		17-10-2002
		DK 700299 T3		23-09-2002
		EE 3118 B1		15-10-1998
		EP 0700299 A1		13-03-1996
		ES 2177579 T3		16-12-2002
		FI 955305 A		06-11-1995
		HU 73693 A2		30-09-1996
		JP 8509745 T		15-10-1996
		NO 954457 A		07-11-1995
		NZ 266031 A		24-04-1997
		PL 311567 A1		19-02-1996
		PT 700299 T		29-11-2002
		RU 2142290 C1		10-12-1999
		WO 9426286 A1		24-11-1994
		SK 138395 A3		05-02-1997
		US 5962650 A		05-10-1999
		ZA 9402251 A		01-11-1994
-----	-----	-----	-----	-----

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPS)